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I Zusammenfassung 
 
Die Regeneration der Sekelettmuskulatur erfolgt durch ansässige adulte 
Stammzellen, die sogenannten Satellitenzellen. Sobald ein Schaden an den 
Muskeln auftritt werden diese Zellen aktiviert und fangen als Myoblasten an zu 
proliferieren. Diese Myoblasten verlassen dann den Zellzyklus, und differenzieren 
zu Myozyten, welche dann miteinander fusionieren, um neue Myofasern zu bilden. 
Dieser Prozess wird adulte Myogenese genannt und wird durch ein Netzwerk von 
Transkriptionsfaktoren kontrolliert. Einer dieser Transkriptionsfaktoren ist MEF2C, 
welcher die Expression solcher Gene begünstigt, die an der späten Differenzierung 
und Fusion beteiligt sind. Allerdings ist MEF2C bereits während der späten 
Proliferation exprimiert. Aus diesem Grund muss die transkriptionelle Aktivität von 
MEF2C kontrolliert werden. Vorangegangene Arbeit dieses Labors hat nTRIP6, 
die nukläre Isoform des LIM Domänen Proteins TRIP6 identifiziert, welches als 
Koaktivator für verschiedene Transkriptionsfaktoren agiert. Basierend auf der 
beschriebenen Interaktion zwischen MEF2C und TRIP6, stelle ich die Hypothese 
auf, dass nTRIP6 als transkriptioneller Koregulator für MEF2C agiert. In 
proliferierenden Myoblasten interagiert nTRIP6 mit MEF2C und wurde zusammen 
mit MEF2C zu den regulativen Abschnitten von MEF2C Zielgenen rekrutiert, was 
zu der Repression von MEF2C führt. Deshalb agiert nTRIP6 als transkriptioneller 
Korepressor für MEF2C. Interessanter weise, ist die Expression von nTRIP6 
während der späten Proliferation und der beginnenden Differenzierung, 
vorrübergehend gesteigert. Dies ist der kritische Moment an welchem die Aktivität 
von MEF2C reprimiert werden muss. Sobald die Funktion von nTRIP6 blockiert 
wird, steigert sich die Expression von Markern der späten Differenzierung, in 
proliferierenden Myoblasten. Dieser Vorgang wurde von einem Defekt in der 
Fusion zu einem späteren Zeitpunkt begleitet. Deshalb scheint es so, als würde 
die zeitliche Regulation der Expression von nTRIP6 die vorzeitige Differenzierung 
verhindern, um eine korrekte Kontrolle über die Fusion zu gewährleisten. 
Zusätzlich zeigen sich regenerierende Muskelfasern, in einem Modell für 
Muskelregeneration in der Maus, bei dem das trip6 Gen in Satellitenzellen 
ausgeschaltet wurde, eine kleinere Größe der Muskelfasern und mehr 
unfusionierte myogene Zellen, im Vergleich zu den Kontrolltieren. 
Zusammengefasst habe ich eine neue molekulare Funktion von nTRIP6 als 
Korepressor von MEF2C gefunden, sowie eine neue Rolle für nTRIP6 als 
Modulator der Dynamik der adulten Myogenese.  
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II Abstract 
 
Skeletal muscle regeneration is carried out by resident adult stem cells, the so-
called satellite cells. Upon muscle damage, these cells get activated and start to 
proliferate as myoblasts. Myoblasts then exit the cell cycle, differentiate into 
myocytes which then fuse to form new myofibres. This process, referred to as adult 
myogenesis, is regulated by a network of transcription factors. One such 
transcription factor is MEF2C, which drives the expression of genes involved in late 
differentiation and fusion. However, MEF2C is already expressed during late 
proliferation. Thus, its transcriptional activity must be controlled. Previous work of 
the lab has identified nTRIP6, the nuclear isoform of the LIM domain protein TRIP6, 
as a co-activator for several transcription factors. Based on a described interaction 
between MEF2C and TRIP6, I hypothesized that nTRIP6 acts as a transcriptional 
co-regulator for MEF2C. In proliferating myoblasts, nTRIP6 interacted with MEF2C 
and was recruited together with MEF2C to the regulatory regions of MEF2C target 
genes, resulting in the repression of MEF2C activity. Thus, nTRIP6 acts as a 
transcriptional co-repressor for MEF2C. Interestingly, nTRIP6 expression was 
transiently increased during late proliferation and early differentiation of myoblasts, 
the critical period when MEF2C activity has to be repressed. When nTRIP6 
function was blocked, the expression of late differentiation markers was increased 
in proliferating and early differentiating myoblasts. This was accompanied by a 
defect in the fusion of myocytes at later time points. Thus, the temporal regulation 
of nTRIP6 expression appears to prevent premature differentiation, which is 
necessary for a proper control of fusion. In addition, in a mouse model of muscle 
regeneration, when the trip6 gene was knocked out in satellite cells the 
regenerated muscle showed a smaller myofibre size and more unfused myogenic 
cells than in the control animals, showing the in vivo relevance of my findings. In 
conclusion, I uncovered a novel molecular function for nTRIP6 as a co-repressor 
for MEF2C, as well as a novel role for nTRIP6 as a modulator of the dynamics of 
adult myogenesis. 
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1. Introduction 
 
1.1 Skeletal muscle regeneration 
	
Muscle tissue contributes to approximately 45% of total body mass and represents 
the largest organ in the human body (Goodpaster et al., 2000). Skeletal muscles 
are responsible for locomotion and force generation and form a huge metabolic 
organ. Skeletal muscles comprise muscle fibre bundles that include individual 
myofibers. Myofibers are multinucleated syncytial cells that are formed by the 
fusion of progenitor cells. Within each of these myofibers many myofibrils are 
located that form a repetitive array of a specialized contractile structure, the 
sarcomere. The sarcomere contains two major types of filaments: thick filaments 
composed of myosin II and thin filaments containing actin and other associated 
proteins. When the muscle contracts, changes in the interaction between myosin 
and the actin permits contraction. Individual myofibers within the muscle are 
exposed to intrinsic tensile force generated when the muscle contracts. This force 
can make the myofibres rupture even during daily life. Thus, skeletal muscle is 
constantly damaged and has to be repaired or regenerated if the damage has led 
to cell death.  
Muscle regeneration can be divided into three phases. In the first phase, the 
destruction phase, the damaged myofibres become necrotized and the damaged 
part is filled by a haematoma. In the next phase (repair phase), phagocytosis of 
the necrotized tissue by infiltrated macrophages takes place. In the last phase 
(remodelling phase), newly formed muscle tissue is generated in a process called 
adult myogenesis (Schiaffino and Partridge, 2008). In skeletal muscle, the 
regeneration process is driven by adult muscle stem cells, the so-called satellite 
cells. The name satellite cells comes from their location between the basal lamina 
and the sarcolemma of the myofibre (Mauro, 1961). Satellite cells form a quiescent 
pool of cells that do not express genes or produce proteins (Kuang et al., 2008; 
McKinnell et al., 2008; Seale et al., 2000). Upon muscle injury satellite cells 
become activated during the remodelling phase. Activation of the satellite cells is 
caused by mechanical stretch to the myofibre itself, that induces the production of 
nitric oxide and consequently the release of HGF that in turn is able to activate 
Introduction	
	
	 10	
satellite cells via c-MET signalling (Tatsumi et al., 1998; Wozniak and Anderson, 
2007; Wozniak et al., 2003). Another activator of satellite cells is Sphingosine-1-
Phosphate (S1P) that is released from the inner leaflet of the plasma membrane 
by cleavage of sphingomyelin (Nagata et al., 2006). Activated satellite cells enter 
the cell cycle and proliferate as a transient amplifying pool of cells, the so-called 
myoblasts. After several rounds of proliferation, myoblasts exit the cell cycle and 
differentiate into committed precursor cells, the so-called myocytes, which finally 
fuse with each other to form myotubes. These different phases of adult myogenesis 
are summarized in Fig. 1. 
 
Figure 1 The different stages of adult myogenesis and the expression of myogenic 
transcription factors 
Adult myogenesis is a multistep process that is regulated by a network of transcription factors. The 
expression of each transcription factor is regulated during the process. Adult myogenesis can be 
recapitulated in vitro from the proliferation phase until fusion. Figure modified from (Bentzinger et 
al., 2012). 
Introduction	
	
	 11	
1.2 Transcription control of adult myogenesis 
 
Adult myogenesis is controlled by a network of transcription factors. To keep 
control over the network, the expression of each transcription factor is temporally 
regulated (Fig. 1). In adult myogenesis three families of transcription factors are 
involved. The paired box transcription factor PAX7, the myogenic regulatory factors 
(MRFs) MYF5, MYOD, MYF4 (myogenin), MRF4 and members of the MEF2 family 
of MADS transcription factors, in particular MEF2C. 
 
1.2.1 The paired box transcription factor PAX7 
 
The paired box transcription factor PAX7 is expressed in resting satellite cells and 
in proliferating myoblasts. Its expression is lost when myoblasts start to 
differentiate into myocytes. In Satellite cells, PAX7 fulfils several functions. On the 
one hand it is responsible for the survival of the cells and their self-renewal (Kuang 
et al., 2008; McKinnell et al., 2008; Seale et al., 2000). On the other hand it keeps 
the cells in an quiescent state by inducing the expression of ID2 and ID3 which 
repress the activity of MRFs (Kumar et al., 2009). It has been shown that mice 
lacking PAX7 do not have quiescent satellite cells and that isolated satellite cells 
from these animals cannot be cultivated (Seale et al., 2000). Moreover, forced 
expression of PAX7 in C2C12 myoblasts prevents the cells from differentiation 
(Zammit et al., 2006). However, although PAX7 is expressed in resting satellite 
cells and keeps them in a quiescent state, it also induces the expression of MRFs 
that drive differentiation (Bajard et al., 2006; Hu et al., 2008; Maroto et al., 1997). 
Thus its pro-differentiation action has to be restricted to a certain time point.  
 
1.2.2 Muscle regulatory factors 
 
Upon activation, satellite cells start to express muscle MRFs. The name muscle 
regulatory factor arises from their ability to drive non-muscle cells into myogenic 
differentiation when ectopically expressed (Braun et al., 1989; Edmondson and 
Olson, 1989; Weintraub et al., 1989). MRFs are part of a superfamily of basic-helix-
loop-helix (bHLH) transcription factors and belong to class II, which show a tissue 
specific expression. In order to be active, MRFs need to either homo-dimerize or 
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hetero-dimerize with class I bHLH transcription factors. Class I bHLH transcription 
factors are ubiquitously expressed and include for example E-proteins such as 
E12/E47. All bHLH transcription factors bind the same consensus sequence called 
E-Box (Blackwell and Weintraub, 1990). Myogenic bHLH differ from other bHLH 
transcription factors by a “muscle recognition motif” in the basic domain (Brennan 
et al., 1991). 
The first MRFs expressed after satellite cell activation are MYF5 and MYOD. Both 
proteins start being expressed at the same time, however they play distinct roles. 
Although MYF5 belongs to the myogenic factors, it is not able to promote 
differentiation on its own, thus it is proposed to function only in myoblasts where it 
promotes their proliferation (Kitzmann et al., 1998; Rawls et al., 1998; Ustanina et 
al., 2007; Valdez et al., 2000). Mice lacking MYF5 suffer from progressive 
myopathy and muscle regeneration defects that come along with increased 
myofibre diameter heterogeneity but also increased number of centralized nuclei 
and high levels of fibrosis. Interestingly the loss of MYF5 does not seem to have 
significant impact on satellite cell activation in contrast to the loss of MYOD that 
goes along with a strong increase in the number of satellite cells (Gayraud-Morel 
et al., 2007; Megeney et al., 1996).  
Expression of MYOD starts upon activation of satellite cells. Its expression is 
maintained in cycling myoblasts and committed myocytes, but is lost in myotubes 
(Bentzinger et al., 2012). In myoblasts, MYOD has been shown to regulate the 
expression of ID3 that prevents the activity of other MRFs in order to promote 
myoblast proliferation (Wyzykowski et al., 2002). Paradoxically, MYOD is also 
required for the progression to terminal differentiation and induces the expression 
of other MRFs such as MYF4 and MRF4 (Gayraud-Morel et al., 2007; Ustanina et 
al., 2007).  
Terminal differentiation is induced by the expression of myogenin (MYF4). 
Myogenin is expressed in myocytes and in myotubes (Bentzinger et al., 2012; 
Cheng et al., 1992). It induces cell cycle exit in myoblasts and the expression of 
structural proteins that are part of the contractile apparatus (Andrés and Walsh, 
1996; Davie et al., 2007). Moreover, myogenin has been shown to be essential for 
the fusion process in vivo since myogenin null mice die perinatal due to a failure in 
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myotubes formation (Knapp et al., 2006; Nabeshima et al., 1993). In contrast to 
other MRFs which can at least partially compensate for each other, the loss of 
myogenin cannot be compensated by other MRFs (Rawls et al., 1995).  
The last family member, MRF4, is expressed in myoblasts during early 
differentiation (Bentzinger et al., 2012). However, the exact role of MRF4 is still not 
known. A study in Myf5/MyoD double null mice has shown that MRF4 can rescue 
partially the phenotype resulting from the deletion of MYF5 and MYOD, showing 
that MYF5 and MYOD act upstream of MRF4 (Hasty et al., 1993).  
1.2.3. The MADS box transcription factors 
 
The transcription factor MEF2C belongs to the MADS domain transcription factors 
and is expressed at low levels in proliferating myoblasts. Its expression is strongly 
increased when early differentiation starts and is maintained in myocytes and 
myofibers (Gossett et al., 1989). Although it does not have any myogenic activity 
on its own, MEF2C acts as a transcription enhancer for other bHLH transcription 
factors such as MYOD (Molkentin et al., 1995). It promotes differentiation by 
inducing the expression of MRF4 and myogenin (Black et al., 1995; Cheng et al., 
1992; Edmondson et al., 1992; Nabeshima et al., 1993) which in turn are 
responsible for final differentiation and fusion. This process is further enhanced by 
the fact that MEF2C also drives its own expression in a positive feedback loop to 
amplify MEF2C signalling (Wang et al., 2001). In addition, MEF2C drives cell cycle 
exit (Badodi et al., 2015; Chen et al., 2000), is involved in the formation of 
podosomes and the generation of the fusion pore prior to fusion (Sens et al., 2010) 
and drives myocyte fusion in an M-Cadherin-dependent manner (Duan et al., 
2012). Finally MEF2C regulates the expression of structural proteins within the 
myotubes such as Myomesin I and II and Desmin (Potthoff et al., 2007). However, 
although MEF2C is needed for myocyte late differentiation and fusion it is already 
expressed in myoblasts (Liu et al., 2014; Mokalled et al., 2012). 
 
1.3  Regulation of transcription factor activity during adult myogenesis 
	
One key element in regulating adult myogenesis is to keep the separation between 
proliferation and differentiation. However, the temporal regulation of the expression 
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of the transcription factors that drive these steps is not sufficient. For example, 
MEF2C drives the expression of late differentiation genes, but is already expressed 
in proliferating myoblasts (Fig. 1). Thus, the activity of transcription factors that 
induce proliferation and those that promote differentiation must also be temporally 
regulated. For example, several mechanisms are known to regulate MEF2C 
activity during the course of myogenesis. One such mechanism is the control of its 
subcellular localization. MEF2C is exported from the nucleus when myoblasts are 
treated with anti- myogenic factor transforming-growth factor b (TGF-b), this 
possibly prevents MEF2C from interacting with MYOD and thus inhibits 
myogenesis (De Angelis et al., 1998). During proliferation MEF2C activity is also 
controlled by the retinoblastoma protein (Rb), which is phosphorylated during 
proliferation and it induces growth arrest in G1 by inactivating E2F when de-
phosphorylated. MEF2C function depends on the binding to MYOD as well as to 
Rb (Novitch et al., 1999). In addition, during proliferation MEF2C is constantly 
degraded by the anaphase promoting complex/cyclosome (APC/C) after it is 
phosphorylated (Badodi et al., 2015). Furthermore, MEF2C transcriptional activity 
is also regulated by transcriptional co-activators such as steroid receptor co-
activator GRIP-1 and p300. GRIP-1 has been shown to bind MEF2C and to 
potentiate its activity and to further recruit p300 to enhance this effect (Chen et al., 
2000; Sartorelli et al., 1997). However, during proliferation, GRIP-1 co-activation 
of MEF2C is prevented by CDK4 by a yet unknown mechanism (Lazaro et al., 
2002). Also transcriptional co-repressors such as histone deacetylases (HDACs), 
in particular class IIa HDACs play a role in MEF2C regulation. During proliferation, 
myoblasts express high levels of HDAC4 and HDAC5 which repress MEF2C 
activity. During differentiation, calcium-calmodulin signalling that is induced by the 
release of intracellular Ca2+ promotes HDAC4 and HDAC5 phosphorylation, which 
results in their export from the nucleus, thus de-repressing MEF2C activity (Lu et 
al., 2000a; McKinsey et al., 2000a). 
Thus, several mechanisms ensure that MEF2C is inactive during the proliferation 
phase and active when cells differentiate. However, the regulation of MEF2C 
activity at the critical point where proliferation stops and differentiation starts is not 
fully understood. Interestingly in a yeast two-hybrid screen MEF2C was found to 
interact with the focal adhesion LIM domain protein TRIP6 (Orchard et al., 2014).  
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1.4  LIM domain proteins  
 
The LIM domain is a cysteine rich motif that was named after the transcription 
factors Lin-11 Isl-1 and Mec3 in which it was first identified (Freyd et al., 1990). 
Spectroscopic analysis showed that LIM domains contain two specific zinc binding 
structures, which coordinates two zinc ions to form two so-called “zinc fingers” 
(Fig.2). In contrast to the zinc fingers found in transcription factors, LIM domains 
serve as protein-protein interaction domains and are not able to bind DNA 
(Kadrmas and Beckerle, 2004). 
 
 
 
Figure 2 Consensus sequence and structure of LIM domains 
 
LIM domain proteins can be divided into three different groups based on their 
sequence similarity and subcellular localization (Dawid et al., 1995). For an 
overview on the different groups see Kadrmas and Beckerle (2004). One of these 
groups contains primarily cytoplasmic proteins, most of which being associated 
with the cytoskeleton. Within this group, the so-called focal adhesion LIM domain 
proteins belong to two families, the Paxilin and Zyxin families. The Zyxin family is 
composed of seven members, Zyxin, Ajuba, LIMD1, LPP, WTIP, Migfilin and 
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TRIP6. As LIM domain proteins, they contain three tandemly arranged C-termimal 
LIM domains, as well as a N-terminal unstructured proline rich region and a highly 
conserved leucine rich sequence that harbours a functional nuclear export signal 
(NES). Therefore, members of the Zyxin family have a predominantly cytosolic 
localization. These proteins are enriched at sites of cell-matrix interaction, in 
particular focal adhesion, as well as at sites of cell-cell adhesion, and are known 
to regulate actin assembly and organisation, adhesion and migration (Smith et al., 
2014). Surprisingly, focal adhesion LIM domain proteins also regulate the 
transcriptional activity of various transcription factors (Guo et al., 2006; Langer et 
al., 2008; Xu et al., 2003). Indeed, these proteins also harbour less characterized 
nuclear targeting regions and are therefore able to shuttle between the cytoplasm 
and the nucleus, where many act as transcriptional co-regulators (Nix and 
Beckerle, 1997).  
 
1.5 The LIM domain protein TRIP6 
	
TRIP6 belongs to the Zyxin family of focal adhesion LIM domain proteins. It was 
first identified in a yeast two-hybrid screen as Thyroid hormone receptor binding 
protein 6 in human cells (Lee et al., 1995). TRIP6 comprises 480 amino acids with 
a mass of 50.9 kDa. Like in the other members of the Zyxin family, three LIM 
domains are present in the C-terminus of TRIP6 (Yi and Beckerle, 1998). In the N-
terminus, TRIP6 harbours a functional NES, and is therefore located in the 
cytoplasm and enriched at sites of focal adhesion (Wang and Gilmore, 2001). The 
exact function of TRIP6 is still not completely revealed but it is known to play a role 
in cell adhesion and migration (Bai et al., 2007; Lai et al., 2005, 2007). Although 
TRIP6 contains a functional NES, it also contains poorly defined nuclear targeting 
sequences, together with sequences that can activate transcription (Wang and 
Gilmore, 2001) . Thus TRIP6 was proposed to shuttle from the cytoplasm to the 
nucleus to regulate transcription (Wang and Gilmore, 2001). However, although 
some reports propose TRIP6 to act as transcriptional regulator (Lin and Lin, 2011; 
Solaz-Fuster et al., 2006), there has been no evidence that TRIP6 really shuttles 
between the cytoplasm and the nucleus.  
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1.6 nTRIP6, the nuclear isoform, of the LIM domain protein TRIP6 
	
Our group has identified a smaller isoform of TRIP6, only present in the nucleus, 
and therefore called nTrip6 (Kassel et al., 2004). TRIP6 showed no evidence of 
nuclear shuttling and its nuclear functions were attributed to nTRIP6 (Diefenbacher 
et al., 2008, 2010, 2014; Kassel et al., 2004). nTRIP6 is generated through the 
usage of an alternative translational initiation codon within the NES encoding 
sequence (Fig. 3). The usage of this second AUG leads to a truncated and non-
functional NES. Thus nTRIP6 is located within the nucleus (Winter 2007). In the 
nucleus nTRIP6 acts as transcriptional co-activator for several transcription factors 
such as AP-1, NF-kB and the glucocorticoid receptor (GR) (Diefenbacher et al., 
2008, 2010, 2014; Kassel et al., 2004). nTRIP6 interacts with these transcription 
factors via its LIM domains, is recruited together with the transcription factors to 
the regulatory regions of target genes and increases their transcription by 
mediating the promoter recruitment of other co-activators such as THRAP3 
(Diefenbacher et al., 2008, 2010, 2014; Kassel et al., 2004). 
 
 
 
 
 
 
 
 
Figure 3 TRIP6 and its nuclear isoform nTRIP6 
TRIP6 and nTRIP6 are translated from two different initiation codons in the same mRNA. 
Translation start at the first start (AUG) is leading to TRIP6, the long isoform containing a functional 
NES. Therefore, TRIP6 is localized in the cytosol. The shorter isoform nTRIP6 is translated from 
the second AUG located within the NES encoding sequence. It does not contain a functional NES 
anymore and is therefore localized in the nucleus. 
 
In a Yeast-two hybrid screen the transcription factor MEF2C was reported to 
interact with TRIP6. However, since the smaller isoform of TRIP6 called nTRIP6 is 
a known co-regulator for transcription factors it is possible that nTRIP6 rather than 
TRIP6 acts as co-regulator for MEF2C. 
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1.7 Aim 
 
The precise regulation of the myogenic transcription factor MEF2C transcriptional 
activity at the critical transition between myoblast proliferation and differentiation is 
not fully understood. In a yeast two-hybrid screen, TRIP6 has been reported to 
interact with MEF2C (Orchard et al., 2014), suggesting that it may regulate MEF2C 
activity. However, since the nuclear isoform nTRIP6 is a known co-regulator for 
other transcription factors, it is possible that not TRIP6 but rather nTRIP6 acts as 
co-regulator for MEF2C. 
Thus, the aim of this study was to investigate whether nTRIP6 acts as 
transcriptional co-regulator for MEF2C, and if so by which mechanism. Moreover, 
given the central role played by MEF2C during adult myogenesis, I studied a 
possible role for nTRIP6 in regulating adult myogenesis in vitro and skeletal muscle 
regeneration in vivo. 
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2 Material and Methods 
2.1 Material 
	
2.1.1Consumables 
	
All cell culture dishes and plates if not stated otherwise were obtained from Greiner 
Bio-One, Frickenhausen 
2.1.2 Chemicals 
 
Chemicals Company 
Collagen I (rat tail) Corning 
Collagenase   Sigma 
Notexin Latoxan 
Tamoxifen 99% Sigma 
 
All other chemicals if not stated otherwise were purchased from Carl Roth, 
Karlsruhe. 
2.1.3 Kits 
	
Kits Company 
Amaxa Nucleofection V Lonza  
Amersham ECL Prime GE Healthcare 
QUIAGEN Maxi Plasmid Kit Quiagen 
GeneJet Gel Extraction Thermo Fischer 
 
2.1.4 Hardware 
	
Device Company 
LSM510Meta Zeiss 
Chemidoc X Touch Imaging Sytem Biorad 
Trans Blot SD Cell  Biorad 
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2.1.5 Enzymes 
	
All enzymes if not stated otherwise were purchased from NEB or Promega. 
2.1.6 Antibodies 
 
Antibody Isotype Concentration Company Ordernumber 
α-actinin Mouse 1:1000(WB) Santa Cruz sc-59953 
α-mCherry Rabbit 1:1000 (IF) Abcam ab167453 
α-mCherry Mouse 1:1000 (WB) Abcam ab125096 
α-GR Rabbit 1:1000 (WB) Santa Cruz sc-1004 
α-HA Rat 1:100(IF) 1:1000 
(WB) 
Sigma 11867423001 
α-HDAC5 Goat 1:100(IF) 1:1000 
(WB) 
Santa Cruz sc-5252 
α-Laminin 
α-Laminin 2 
alpha 
Rabbit 
Rat 
1:1000(IF) 
1:1000(IF) 
Sigma 
Abcam 
L9393 
ab11576 
α-Mef2C Rabbit 1:100(IF) 1:1000 
(WB) 
Cell Signalling D80C1 
α-MyoD Rabbit 1:100(IF) ThermoFischer PA5-23078 
α-myogenin Mouse 1:100(IF) 1:1000 
(WB) 
DSHB F5D-s 
α-myHC (MYH3) Mouse 1:100(IF) 1:1000 
(WB) 
DSHB F1.652 
α-p21 Mouse 1:100(IF) 1:1000 
(WB) 
BD Bioscience 556430 
α-Trip6 Rabbit 1:100(IF) 1:1000 
(WB) 
Self made  
Secondary antibodies 
α-mouse 
Alexa488 
Goat 1:10000 ThermoFischer A-11001 
α-mouse 
Alexa546 
Goat 1:10000 ThermoFischer A-11030 
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α-rabbit Alexa 
488 
Goat 1:10000 ThermoFischer A-11059 
α-rabbit Alexa 
546 
Goat 1:10000 ThermoFischer A-10040 
α-rat Alexa 546 Goat 1:10000 ThermoFischer A-11081 
α-mouse- HRP  1:2000 Dako P0260 
α-rabbit-HRP  1:2000 Dako P0448 
α-rat-HRP  1:2000 Dako P0450 
     
 
2.1.7 Buffers 
	
General buffers 
TAE 40 mM Tris acetate, 1 mM EDTA[pH 8.2 - 8.4 (at 25°C)] 
RIPA: 50mM Tris pH 7.5; 150mM NaCl; 1% NP-40; 0.5% 
NaDoc; 
0.5% SDS 
Gly Gly 25mM Glycylglycin; 15mM MgSO4; 4mM EGTA; pH 
7,8 
NID 10mMTrisHCl pH 8.3; 50mM KCl; 2,5mM MgCl2; 
0,1mg/ml Gelatine; 0.45%NP40;0,45%TWEEN20 
  
ChIP buffers 
 
Swelling Buffer 25mM Hepes pH7.8; 1.5mM MgCl2; 10mM KCl; 
0.1%NP-40; 1mM DTT; 0.5mM PMSF; 1xPIC 
Sonication Buffer 50mM Hepes pH 7.9; 140mM NaCl;1mM EDTA 1% 
TritonX-100;0,1%SDS; 0.5mMPMSF; 1x PIC 
Dilution buffer 0,01%SDS, 1% Triton-X-100, 2mM EDTA, 16.7mM 
TrisHCl pH8.1, 167mM NaCl 
Low salt buffer 0,1%SDS, 1%Triton-X-100, 2mMEDTA, 20mM 
TrisHCl pH8.1, 150mM NaCl 
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High salt buffer 
 
0.1%SDS, 1% Triton X-100, 2mM EDTA, 20mM 
TrisHCl pH8.1, 500mM NaCl 
Elution Buffer  Normal: 0.1M NaHCO3 , 1% SDS (add fresh) 
Re-ChIP: 10mM DTT  
 
 
  
Material	and	Methods	
	 23	
Immunofluorescence staining 
 
Fixation buffer 2% Paraformaldehyde in PBS -/-  pH 7.2 
Permeabilization buffer 0.5% Triton X-100 in PBS -/- 
Blocking buffer 5% BSA in PBS -/- pH 7.2 
 
Protein measurement according to Lowry 
Lowry 1 20g/L Na2CO3; 4g/L NaOH in ddH2O 
Lowry 2 1% CuSO4 
Lowry 3 2% NaK Tartrat 
Lowry 4 1% Lowry II buffer; 1% Lowry III buffer in Lowry I buffer 
 
SDS-PAGE and Western Blot 
Separating gel 10% Acrylamid:Bisacrylamid; 375mM TrisHCL (pH 
8.8); 0.1% SDS; 0.1% APS; 0.04% TEMED 
Stacking gel 5% Acrylamid:Bisacrylamid; 125mM TrisHCL (pH 
6.8); 0.1% SDS; 0.1% APS; 0.1% TEMED 
Electrophoresis buffer 25mM Tris; 192mM Glycin; 0.1% SDS 
2x Sample buffer 125mM TrisHCL (pH 6.8); 4% SDS; 20% Glycerol; 
0.01% Bromphenol blue; 2% 2-Mercaptoethanol 
TBST 20mM Tris; 150mM NaCl; pH 7,6)+ 0,05% TWEEN 20 
Blotting buffer 20mM Tris; 192mM Glycine; 10% Methanol 
Blocking buffer 5% skimmed milk powder; TBS 
 
Luciferase assay and liquid β-Galactosidase assay 
Reaction Buffer 2mM ATP; 1mM DTT in GlyGly Buffer 
Substrate 1mM Luciferin 1:10 in GlyGly Buffer 
Solution A  Sodium Phosphate 0,1M  
Solution B ONPG 1mg/ml 
Solution C 100mM MgCl2 , 4,48M β-Mercaptoethanol 
 
Material	and	Methods	
	 24	
2.1.8 Bacterial strains and growth media 
2.1.8.1 Bacterial strains 
 
E. coli DH5α (Genotype: supE44DlacU169 (FlacZDM15) hsdR7 recA1 gyrA96 thi-
1 relA1) 
2.1.8.2 Bacterial growth media 
Luria Both (LB): Yeast extract  10g/l 
   NaCl     5g/l 
   Tryptone    5g/l 
   pH 7.5 
2.1.9 Cell lines and cell culture media 
2.1.9.1 Cell line 
 
C2C12   Mus musculus muscle myoblast cells (ECACC No.: 91031101) 
2.1.9.2 Cell culture media 
 
C2C12 growth medium DMEM + 10% FCS  
C2C12 differentiation medium DMEM + 0.5% Horse Serum 
2.1.10 Plasmids 
	
pcDNA3.1(+) Empty vector, basic mammalian expression 
cloning vector 
pcDNA3.1(+)HA- mCherry-NLS Contains the cDNA of a functional Nuclear 
Localization Signal (NLS) sequence fused 
to the cherry-red fluorescent protein 
(mcherry) under the control of a CMV 
promoter.  
(provided by Margarethe Litfin, ITG, KIT) 
pcDNA3.1(+)HA-mCherry-NES Contains the cDNA of a functional Nuclear 
Export Signal (NES) sequence fused to the 
cherry-red fluorescent protein (mcherry) 
under the control of a CMV promoter.  
Material	and	Methods	
	 25	
(provided by Markus Diefenbacher, ITG, 
KIT) 
pcDNA3.1(+) –mCherry-NLS-ID 1 Contains the cDNA of nTrip6175-187 fused to 
a NLS sequence and to the cherry-red 
fluorescent protein (mCherry) under the 
control of a CMV promoter.  
(provided by Markus Diefenbacher, 
ITG,KIT) 
 
pcDNA3.1(+)-mCherry-NLS-ID1c Contains the scrambled cDNA of nTrip6175-
187 fused to a NLS sequence and to the 
cherry-red fluorescent protein (mCherry) 
under the control of a CMV promoter.  
(provided by Markus Diefenbacher, 
ITG,KIT) 
 
 
pcDNA3.1(+)-mCherry-NLS-ID2 
 
Contains the cDNA of nTrip6257-270 fused to 
a NLS sequence and to the cherry-red 
fluorescent protein (mCherry) under the 
control of a CMV promoter.  
(provided by Markus Diefenbacher, 
ITG,KIT) 
 
pcDNA3.1(+)-mCherry-NLS-ID2c Contains the scrambled cDNA of nTrip6257-
270 fused to a NLS sequence and to the 
cherry-red fluorescent protein (mCherry) 
under the control of a CMV promoter.  
(provided by Markus Diefenbacher, 
ITG,KIT) 
 
pcDNA3.1(+)-MEF2C Contains the cDNA of MEF2C  
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(provided by Eric N Olson, University of 
Texas Dallas) 
pGL3-TATA-DesMef3-Luc Contains the Luciferase gene driven by 
three copies of the Mef2C response element 
(provided by Eric N Olson, University of 
Texas Dallas) 
pcDNA3.1(+)β-Galactosidase Contains the cDNA of the enzyme β-
Galactosidase 
pcDNA3.1(+)HAnTrip6 pcDNA3.1(+) vector containing the cDNA of 
mouse nTrip6 fused to an HA tag at its N-
terminus. 
(provided by Oliver Dahley ITG,KIT) 
pcDNA3.1(+)HAnTrip6∆ID1 pcDNA3.1(+) vector containing the cDNA of 
mouse nTrip6 fused to an HA tag at its N-
terminus lacking the amino acids from 175-
187. 
pcDNA3.1(+)HAnTrip6∆ID2 pcDNA3.1(+) vector containing the cDNA of 
mouse nTrip6 fused to an HA tag at its N-
terminus lacking the amino acids from 257-
270. 
 
pcDNA3.1(+)HA-MCS-VN Contains the coding sequence 1-172 of the 
N-terminal part of Venus fluorescent protein 
(VFP) under the control of a CMV promoter.  
 
pcDNA3.1(+)HA-MCS-VC Contains the coding sequence 155-238 of 
the C-terminal part of Venus fluorescent 
protein (VFP) under the control of a CMV 
promoter.  
 
The following constructs were cloned in the MCS of the above described vectors 
using KpnI and XbaI: 
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pcDNA3.1(+)HATrip6-VN  
pcDNA3.1(+)HAnTrip6-VN  
pcDNA3.1(+)HAnTrip6-VC  
pcDNA3.1(+)HAnTrip6-Nter-VN  
pcDNA3.1(+)HAnTrip6-LIMonly-VN  
pcDNA3.1(+)HAnTrip6∆ID1-VN  
pcDNA3.1(+)HAnTrip6∆ID2-VN  
pcDNA3.1(+)HAMef2C-VC  
pcDNA3.1(+)HAHDAC4-VN  
pcDNA3.1(+)HAHDAC5-VN  
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2.1.11 Primers 
	
Genotyping 
Trip6 flox/flox 
mTrip6-28F tcaccttttctcccttgcctgcctg 
mTrip6-29R ggtacccccggaggctgataacag 
 
Pax7 CRE ERT2 
gtPax7CreERT2for GCTGCTGTTGATTACCTGCC 
gtPax7CreERT2mrev CAAAAGACGGCAATATGGTG 
gtPax7CreERT2wtrev CTGCACTGAGACAGGACCG 
 
ChIP 
pmDesMef2QChIPfor CCCAGAACGCCTCTCCTGTACCTT 
pmDesMef2QChIPrev CAGCCGTCTCCCTAGCAGCAACA 
pmTnni2QChIPfor1 GCTGGCATCTTGAACTCGTC 
pmTnni2QChIPrev1 CCAGGCCACACAGAAGAAC 
pmMyoglobinQChIPfor GGGCTTGTGCAAGTCCAGACAGTG 
pmMyoglobinQChIPrev CCCTTCCTGCTACCGTGCTCAAC 
pmMyom2QChIPfor  GAGCAGAGTACCCTGGGACG 
pmMyom2QChIPrev TTATGGCCAGAGGAGGTGCTA 
 
2.1.12 siRNA 
	
Trip6 siRNA 5’-cag ucu gga ugc uga gau aga (dTdT)-3’ 
Control siRNA 5’-agg uag ugu aau cgc cuu gtt (dTdT)-3’ 
2.1.13 Fluorescent Dyes 
	
DRAQ5TM    
Synthetic fluorescent dye with a high affinity to DNA, thus it can be used to highlight 
the nuclei of living and fixed cells or tissue. 
Excitation (Max): 647nm 
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Emission (Max): 670nm 
2.2 Methods 
 
2.2.1 Animals and animal handling 
	
Experiments were performed on C57/BL6 mice. Use and care of the animals was 
approved by German authorities (Tierschutzkommission of the 
Regierungspräsidium Karlsruhe, licenses G-232/11 and G261/15) according to 
national law (TierSchG §7).  
2.2.1.1 Trip6 conditional knockout mouse (Cre/LoxP System) 
 
The Trip6 conditional knockout mouse was generated by crossing two different 
mouse lines: a Trip6 floxed line, in which loxP sites were introduced after exons 1 
and 9 of the Trip6 gene (Markus Winter, ITG KIT), and a mouse expressing the 
tamoxifen-inducible Cre-Recombinase (Cre-ERt2) under the control of the pax7 
promoter, thus exclusively expressed in satellite cells (Murphy et al., 2011). Cre-
Recombinase is fused to the ligand binding domain of the Estrogen Receptor (ER) 
carrying the T2 mutation, which renders the receptor insensitive to endogenous 
Estrogen but sensitive to Tamoxifen. Upon Tamoxifen binding to Cre-ERT2, the 
fusion protein shuttles to the nucleus where the Cre-Recombinase recognizes the 
loxP sites and deletes the Trip6 gene in satellite cells (Fig. 4) 
 
 
 
 
 
 
 
 
Material	and	Methods	
	 30	
Figure 4 Satellite cell-selective conditional trip6 knockout mouse 
2.2.1.2 Genotyping  
Mouse tails were digested overnight in 200µl NID-buffer + 2µl (10mg/ml) 
Proteinase K at 55°C. Next day Proteinase K reaction was stopped by heating up 
to 95°C for 30min. Samples were then centrifuged for 15min at 13000rpm at 4°C. 
Genotyping was performed via PCR using the primers listed in 2.1.10.  
Trip6 flox/flox  PCR program 
5x Buffer 10µl  95°C 5min 
10mM dNTP 1µl  95°C 1min 
10µM Primer 2µl  71°C 1min 
Taq Polymerase 0.25µl  72°C 1 min 
DNA 4µl  35-40 cycles 
Total Volume 50µl  72°C 10min 
 
 
  8°C store 
Pax7-Cre-ERT2  PCR program 
5x Buffer 10µl  95°C 5min 
10mM dNTP 1µl  95°C 1min 
10µM Primer 2µl  62°C 1min 
Taq Polymerase 0.25µl  72°C 1 min 
DNA 4µl  35-40 cycles 
Total Volume 50µl  72°C 10min 
   8°C store 
2.2.1.3 Treatment with Tamoxifen 
Mice were injected intraperitoneally on 5 consecutive days with 5µl/g body weight 
Tamoxifen from a 10mg/ml stock solubilized in peanut oil.  
2.2.1.4 Degeneration of murine M soleus 
Degeneration of soleus muscle was induced as described in (Danieli-Betto et al., 
2005, 2010) Animals were anesthetized by an intraperitoneal injection of Ketamin 
and Xylasin (100mg/kg body weight Ketamine, 16 mg/kg body weight Xylazine) 
inject 0.1 ml/10 g body weight). 10µl of a 5ng/µl Notexin solution diluted in sterile 
PBS-/- were injected unilaterally in the exposed soleus muscle, through a small 
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cutaneous incision. Animals were sacrificed by cervical dislocation after 7 days, 
10, 14 and 28 days of regeneration. 
2.2.1.5 Preparing and sectioning skeletal muscle tissue 
Mice were sacrificed by cervical dislocation at 3-6 weeks of age. M. soleus was 
dissected by cutting the tendons, then fixed in a stretched position and frozen in 
liquid nitrogen. The muscle was cut in two halves with a scalpel. Half of the muscle 
was then fixed on a mounting carrier using O.C.T. compound (Tissue-Tek) and 
10µm thick cryosections were cut using a cryostat. These sections were then 
transferred onto a glass slide for further processing.  
2.2.1.6 Immunofluorescence staining of muscle tissue sections 
Muscle sections were fixed for 5 minutes in fixation buffer at room temperature. 
After fixation the sections were washed 3 times for 5 minutes in PBS-/-. For 
permeabilization the sections were incubated for 10 minutes in 0.5%Triton-X-100 
in PBS-/- and afterwards washed again. Sections were blocked in blocking solution 
for 1h at room temperature. The 1st antibody was diluted at an appropriate 
concentration in blocking solution and incubated on the section overnight at 4°C. 
On the next day sections were washed and the appropriate secondary antibody 
was applied for 1h at room temperature in the dark. After washing three times with 
PBS -/- the sections were mounted with Mowiol 4-88 and the sections were 
subjected to analysis. 
2.2.1.7 Microscopy and Quantification of the cross section area of 
regenerating myofibers 
Muscle sections were stained according to 2.2.5 with an antibody against laminin 
to visualize the basal lamina of the fibres. Microscopy images were acquired using 
a 10X Plan- Apochromat objective. On each picture single myofibres were 
segmented automatically and the minimum Feret’s Diameter was measured using 
the ImageJ Software.  
2.2.1.8 Preparation of isolated fibres of Extensor digitorum longus (EDL) 
Mice were sacrificed by cervical dislocation. EDL was dissected as described in 
2.2.1.5. The digestion was performed in DMEM + 0.2% Collagenase for 1h at 37°C. 
Afterwards the fibres were dissociated by pipetting the muscle up and down in a 
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cut Pasteur pipet with decreasing opening. The released fibres were collected and 
further processed as described in 2.2.1.6. 
2.2.2 Cell culture methods 
2.2.2.1 Cell culture conditions 
All cells were cultured at 6% CO2, 95% humidity at 37°C. Manipulation of cells was 
performed under a sterile hood. Media, buffers and glassware were sterilised 
before work (120°C, 1.4 bar, 20min). 
2.2.2.2 Passaging and seeding of cells 
After removing the medium the cells were washed with PBS lacking Ca2+ and Mg2+. 
Then the cells were treated with a Trypsin solution and incubated for 2 minutes in 
the incubator. The trypsin reaction was stopped by adding medium to the dish and 
the cells were resuspended carefully. Thereafter the cells were counted and 
transferred to a new dish. To determine the cell number a Neubauer chamber was 
used. 
Format Cell number 
15 cm Dish 2,5x105 
24 well plate 1x104 
IBIDI 5x103 
 
2.2.2.3 Transfection of C2C12 cells with Promofectin 
Cells were seeded according to 2.2.2.2 and transfected according to 
manufacturer’s protocol, with appropriate amounts of DNA 
Format Amount DNA [ng] Volume Medium [µl] Transfection Mix [µl] 
24 Well plate 1000 500 50 
IBIDI 400 150 25 
2.2.2.4 Transfection of C2C12 cells with Amaxa 
1x106 cells were transfected with either 6µg of plasmid DNA or 600pmol of siRNA 
according to manufacturer’s protocol. Before seeding cells were stained with trypan 
blue and counted to estimate the number of viable cells.  
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2.2.3 Protein methods 
2.2.3.1 Protein isolation (in RIPA buffer) 
Cells were washed twice with ice cold PBS, scraped and transferred into 15ml 
Falcon tube. The cells were centrifuged at 1,200rpm, 4°C for 3min and the 
supernatant was discarded. The cell pellet was resuspended in 20μl RIPA buffer 
(supplemented with PIC) and sonicated for 5min (low intensity)  
2.2.3.2 Measurement of total protein concentration according to Lowry 
250μl Lowry I-buffer were added to 4μl of the sonicated protein lysate. 500μl Lowry 
IV-buffer was added to all samples and incubated 5min at RT. 50μl Folin was 
added and incubated for 30 minutes at RT. The protein concentration was 
assessed by spectrometry at 595nm wavelength and the extinction was measured 
and compared to a standard curve. 
2.2.3.3 Separation of Proteins via SDS-Page 
Proteins were separated according to their size using an electrical field (Laemmli, 
1970)The polyacrylamid gels were casted according to (Sambrook et al., 1989). 
The gels were run in a mini gel system (Hoefer, San Francisco, USA) at 100V for 
1h. 
2.2.3.4 Western Blotting 
After the separation on the gel, the proteins were transferred to an Immobilon-P 
membrane soaked in methanol and activated before used. For the transfer a semi-
dry blotter at 1mA/cm2 for 1h was used with western blot buffer. After the blotting 
the membrane was incubated in blocking buffer for 1h at room temperature. Then 
the primary antibody diluted in the blocking buffer was incubated on the membrane 
over night at 4°C under constant shaking. The next day the membrane was washed 
with TBST three times for 5 minutes at room temperature. The secondary antibody 
(conjugated with HRP) was diluted in blocking buffer and the membrane was 
incubated with the antibody for one hour at room temperature. The membrane was 
then washed with TBST three times for 5 minutes. The detection of the specific 
signal of the HRP was done using an ECL Western Blot kit and the Biorad ECL 
Imaging machine 
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2.2.4 DNA methods 
2.2.4.1 PCR (Pfu-DNA-Polymerase) 
A sequence specific primer pair was used in order to amplify DNA-fragments by 
using the Pfu-DNA-polymerase (Promega). 0.1µg of DNA, 0.4mM of each Primer, 
10% DMSO, 0.2mM dNTPs, 1U Pfu-DNA-Polymerase and the appropriate volume 
of 10x PCR-Buffer (Promega) were mixed on ice. The reaction was carried out in 
a Perkin-Elmer-Thermocycler (Norwalk, USA). Annealing temperature and time 
was adapted to each PCR. Elongation was carried out at 72°C and the time 
adapted to the size of the fragment (2min/kb).  
2.2.4.2 DNA digestion 
2 units of the corresponding restriction endonuclease were used to digest 1µg of 
plasmid DNA. The total volume of the reaction mix was 10 times the volume of the 
enzyme/glycerol solution. In order to achieve the optimal salt and pH-conditions for 
the enzymes to work best, a corresponding buffer was used, that was 10 times 
concentrated. The reaction mix was incubated, if not stated otherwise by the 
supplier, at 37°C for 2h. 
2.2.4.3 Electrophoresis 
In order to separate DNA fragments according to their size, DNA was subjected to 
an electric field within a 1% agarose gel matrix. To produce a 1% agarose gel the 
corresponding amount of agarose was weighed and dissolved in 1x TAE buffer. 
After dissolving the agarose and cooling down Ethidium bromide was added and 
the gel was cast. The separation was achieved by applying an electric current with 
a voltage of 100V. The separated DNA was visualized using UV-light. 
2.2.4.4 Isolation of DNA Fragments out of Agarose Gels 
Fragments of the size of interest were cut out of the gel using a scalpel at an UV-
light table. The DNA was purified out of piece of gel using the GeneJet Gel 
Extraction Kit. 
2.2.4.5 Phenol-Chloroform extraction 
DNA solution was mixed with 1vol of Phenol:Chlorofom:Isoamylalcohol (24:1:1) 
and vortexed for one minute. Centrifugation was performed with 14000rpm for 5 
minutes. DNA containing phase was transferred into a fresh reaction tube and 
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mixed with 1vol of Chloroform: Isoamylalcohol (24:1) and vortexed. After that 
centrifugation was performed with 14000rpm for 5 minutes and the aqueous phase 
was transferred to a fresh reaction tube and mixed with 2.5vol 100%EtOH with 
20µg of Glycogen and 1/15 Na-actetate. Precipitation was performed for at least 
one hour at -20°C. Centrifugation was performed with 14000rpm at 4°C for 30 
minutes DNA pellet was washed with 75% EtOH and after drying resuspended in 
20-50µl ddH2O. 
2.2.4.6 Ligation of DNA-fragments 
The ligation reactions were performed using the T4 DNA ligase according to 
manufacturer’s instruction (NEB). The reaction mix was incubated O/N at 16°C. 
2.2.4.7 Colony PCR 
A colony PCR was performed in order to screen bacterial clones. Neither the PCR 
program nor the PCR mix was altered. But instead of adding DNA, an E. coli clone 
was picked with a yellow pipette tip and first transferred into the PCR mix and then 
onto a fresh agar plate containing the appropriate selection marker 
2.2.4.8 Transformation of E. coli (DH5α) 
100µl of chemically competent E. coli (DH5α) were thawed on ice and 0.1µg of 
plasmid DNA was added. The mix was incubated on ice for 30min and then the 
bacteria were subjected to heat shock treatment for 30sec at 42°C in a heating 
block. The bacteria were then placed on ice for 2min and 1ml LB-medium was 
added. The transformed bacteria were incubated at 37°C for 1h before adding the 
selection marker. For selection, the bacteria were plated onto LB agar plates that 
contained the selection marker or were directly transferred into 100ml of LB-
medium containing the selection marker. The bacteria were allowed to grow for 
24h at 37°C. 
2.2.5 Assays 
2.2.5.1 Bimolecular fluorescent complementation assay (BiFC) 
The BiFC (Hu et al., 2002) assay is a live cell protein-protein interaction assay 
based on the complementation of the fluorescence of a fluorescent protein (Venus 
or YFP) split into its C-terminal and N-terminal halves that are each fused to the 
two proteins of interest. If the two proteins interact with each other, the two halves 
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of the fluorescent protein are in close proximity and can fold as the native protein, 
and thus fluorescence can be observed. C2C12 cells were transfected according 
to 2.2.2.3. The next day medium was changed and the cells were subjected to 
microscopic analysis using the LSM510 Meta and a 40x Apochrom oil Objective.  
2.2.5.2 Luciferase Reporter Gene Assay 
C2C12 cells were seeded according to 2.2.2.2 and grown overnight. The next day 
the cells were transfected using Promofectin as described in 2.2.2.3. Up to 400ng 
of plasmid DNA were transfected and 100 ng of the reporter construct pGL3-TATA-
DesMef3 and 50ng of pcDNA3.1β-galactosidase as control. The cells were 
incubated for 48h in a cell incubator at 6% CO2, 95% humidity at 37°C. After 
incubation the cells were washed twice with ice cold PBS (-/-) and lysed with 100µl 
Passive Lysis buffer (Promega) for 15min on ice. After lysis, 20 µl of the lysed cells 
were transferred into a white 96well plate and subjected to luciferase 
measurement. 70µl of the reaction buffer together with 20µl substrate were injected 
automatically in each well. The luminescence was measured for 2 seconds. 
2.2.5.3 Liquid β-Galactosidase Assay 
20µl of cell lysate from 2.2.5.2 were mixed with the reaction solution (See buffers) 
Incubation was performed for 10-30min at 37°C in the dark. Quantification was 
performed in a photometer measuring at 420nm.  
2.2.5.4 Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation was performed on C2C12 cells seeded at a density 
of 5x105 in a 15cm dish and grown for 48h. Cells were crosslinked for 10 min with 
formaldehyde (540µl in 20ml DMEM). After washing with cold PBS -/- the 
crossliniking was stopped by adding 10ml of 1x Glycin Buffer (Active Motif ChIP-IT 
Express) for 5 minutes. After washing with ice cold PBS-/- cells were harvested in 
20ml ice cold PBS supplemented with 0.5mM PMSF and centrifuged at 1200rpm 
for 5 minutes at 4°C. The cell pellet was resuspended in 10 vol Swelling buffer and 
kept on ice for at least one hour. Centrifugation was performed at 2000rpm for 5 
min and the cell pellet was resuspended in 4 times 350µl Sonication buffer. The 
chromatin was sheared into 200-1000 bp fragments by sonication with 30sec 
pulses separated by 30sec pauses for 1h at middle intensity (Bioruptor, Diagenode, 
Liège, Belgium). To determine shearing efficiency, 5μl of the sheared chromatin 
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were diluted with 15μl ddH2O. The sheared chromatin was subjected to gel 
electrophoresis on a 2% agarose gel. To estimate the amount of chromatin the cell 
lysate was measured using the Nano Drop. For immunoprecipitation 65µg 
chromatin was mixed with 1350µl ChIP dilution buffer and 2.5µg of the antibody 
and incubated O/N at 4°C on a rotor. The next day 20µl of protein G-conjugated 
magnetic beads were incubated with the immunoprecipitated chromatin for 2h at 
4°C on a rotor. The beads were then washed once with low salt buffer, 4 times with 
high salt buffer and then once with 1x TE buffer (1000µl). All washing steps were 
performed for 5 minutes under rotation at 4°C. After the last washing step the 
beads were incubated with 400µl elution buffer for 10 minutes at 65°C. The 
supernatant was transferred into a fresh Eppendorf tube, 21µl NaCl (4M) were 
added and the mix was incubated O/N at 65°C under shaking. The next day, DNA 
was purified using Phenol-Chloroform extraction (2.2.4.5) and the precipitated 
DNA was dissolved in 50µl ddH2O.  
2.2.5.5 Double Chromatin immunoprecipitation or ReChIP 
After the first ChIP, the ReChIP was performed by eluting the chromatin with 100µl 
DTT (10mM) for 30 minutes at 37°C and shaking. Afterwards the eluted chromatin 
was diluted in ChIP dilution buffer, and the second immunoprecipitation was 
performed as described in 2.2.5.4. 
2.2.6 Statistical analysis 
Where indicated, significant differences were assessed by t-test analysis, with 
values of P<0.05 sufficient to reject the null hypothesis. 
For the animal experiments, multiple comparisons between groups were made 
using ANOVA and Tukey’s post-hoc analysis.  
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3 Results 
 
3.1 nTRIP6 acts as a co-repressor for MEF2C 
	
A search for MEF2C interacting proteins in the IntAct Database (Orchard et al., 
2014) revealed TRIP6 as an interaction partner for MEF2C. If indeed TRIP6 co-
regulates MEF2C it must be present in the nucleus. However, proteins from this 
family of LIM domain proteins all have an NES and are therefore mostly cytosolic. 
Nevertheless, some of them have been detected at low levels in the nucleus or can 
shuttle between the cytoplasm and the nucleus (Kadrmas and Beckerle, 2004; Nix 
and Beckerle, 1997). Therefore, I tested whether TRIP6 is present in the nucleus 
of C2C12 myoblasts as a prerequisite to act as a co-regulator for MEF2C. To do 
so I performed immunofluorescence staining using an antibody against TRIP6. The 
staining shows a strong cytosolic staining and also a weaker nuclear staining (Fig. 
5a).  
 
 
 
Figure 5 Subcellular localization of TRIP6 and nTRIP6 in myoblasts 
a) C2C12 myoblasts were stained with an antibody recognizing both isoforms TRIP6 and nTRIP6. 
Nuclei were counterstained with DRAQ5. b) C2C12 cells were transfected with either an empty 
vector or an expression vector for TRIP6 or nTRIP6 fused to an HA-tag. Detection was performed 
using an anti-HA antibody and nuclei were counterstained with DRAQ5. (a-b) Representative 
confocal images are shown, scale bars: 10µm 
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This result suggests that TRIP6 might be shuttling from the cytosol to nucleus. To 
confirm this result, I expressed either an empty control vector or an expression 
vector for HA-tagged TRIP6. Overexpression of HA-TRIP6 led to an exclusive 
cytosolic staining. Thus, it is unlikely that the signal in the nucleus observed with 
the anti-TRIP6 antibody is TRIP6. (Fig. 5b). In our group, a shorter isoform of 
TRIP6 was identified which is exclusively present in the nucleus and therefore 
called nTRIP6 (Kassel et al., 2004). Indeed, ectopic expression of HA-nTRIP6 led 
to an exclusive nuclear staining (Fig. 5b). Taken together these results show that 
also in myoblasts, TRIP6 is present only in the cytosol, whereas nTRIP6 is located 
in the nucleus. Thus, if one of the isoforms acts as transcriptional co-regulator for 
MEF2C it must be nTRIP6. 
 
To confirm that MEF2C interacts with nTRIP6 and not with TRIP6, I used the 
bimolecular fluorescent complementation (BiFC) assay, a protein-protein 
interaction assay based on the complementation of the fluorescent protein Venus 
(Hu et al., 2002). MEF2C was fused to the C-terminal half of Venus (VC) while 
TRIP6 and nTRIP6 were fused to the N-terminal half of Venus (VN). 
Immunofluorescence analysis of the constructs transfected in C2C12 cells showed 
that the fusion to VC or VN did not influence their subcellular localization (Fig. 6).  
 
 
 
Figure 6 BiFC fusion Proteins are properly expressed and localized 
C2C12 cells were transfected with expression vectors for HA-tagged versions of MEF2C fused to 
VC, TRIP6, nTRIP6, nTRIP6 lacking interaction domain 1 (DID1) or interaction domain 2 (DID2) 
fused to VN. Cells were then subjected to immunofluorescence analysis with an antibody against 
the HA tag and nuclei were counterstained with DRAQ5. Left panel: representative images are 
shown (scale bars: 10µm). Right panel: the same constructs were transfected into C2C12 cells and 
cell lysates were analyzed by Western Blotting using an anti-HA antibody and an anti-GR antibody 
as loading control. 
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Venus complementation was observed in only 7,3 % of the cells transfected with 
MEF2C-VC and TRIP6-VN, whereas it was observed in over 73% of the cells 
transfected with MEF2C-VC and nTRIP6-VN (Fig. 7). Furthermore, the BiFC signal 
was restricted to the nucleus. This result confirms that MEF2C interacts with 
nTRIP6 in the nucleus and not with TRIP6 in the cytosol. Preliminary work from the 
group showed that nTRIP6 interacts with MEF2C via its N-terminal pre-LIM region. 
Furthermore, two protein-protein interaction domains were identified in the N-
terminal region of nTRIP6 (Diefenbacher et al., 2014). These domains are thus 
good candidates for mediating the interaction with MEF2C. These putative 
interaction domains will be further referred to as interaction domain 1 (ID1) and 
interaction domain 2 (ID2) that comprise the amino acids 175-187 and 253-265, 
respectively. To study the contribution of ID1 and ID2 to the interaction between 
MEF2C and nTRIP6, I designed deletion constructs lacking either of these domains 
and fused them to the N-terminal part of Venus. All deletion constructs were 
present in the nucleus and expressed at similar levels (Fig. 6). Deletion of either 
ID1 or ID2 led to a significant reduction in the interaction between nTRIP6 and 
MEF2C in the BiFC assay: only about 50% of the transfected cells showed Venus 
complementation (Fig. 7). This shows that both protein-protein interaction sites 
play a role in the binding of nTRIP6 to MEF2C.  
 
Figure 7 nTRIP6 interacts with MEF2C via distinct domains in the N-terminal region 
C2C12 cells were co-transfected with expression vectors for MEF2C fused to the C-terminal half of 
Venus (VC) and either TRIP6 or nTRIP6, nTRIP6 lacking interaction domain 1 (∆ID1) or nTRIP6 
lacking interaction domain 2 (∆ID2) fused to the N-terminal half of Venus (VN), together with 
mCherry fused to a nuclear export signal (NES) as a transfection control. Left panel, Venus 
complementation (Compl.) was imaged by confocal microscopy and representative images are 
shown (scale bars: 10µm). Right panel, the number of cells showing Venus complementation is 
presented as percentage of transfected, mCherry positive cells (mean ±SD of three independent 
experiments). 
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To confirm this result, I made use of genetically encoded blocking peptides that 
encode either ID1 or ID2 fused to mCherry and to a nuclear localization sequence 
to target them to the nucleus and therefore avoid any interference with TRIP6 in 
the cytosol. As negative controls I used a scrambled versions of the peptides (ID1c, 
ID2c) (Diefenbacher et al., 2014). The hypothesis was that if ID1 and ID2 are 
indeed involved in the interaction, the peptides would act as competitive inhibitors 
and interfere with the binding between nTRIP6 and MEF2C. C2C12 cells were 
transfected with nTRIP6-VN and MEF2C-VC and co-transfected with either the 
blocking peptides or the control peptides. The mCherry fluorescence signal 
confirmed that both peptides and their corresponding control peptides were 
properly localized to the nucleus (Fig. 8).  
 
 
 
Figure 8 Blocking peptides inhibit the interaction between MEF2C and nTRIP6 
C2C12 cells were co-transfected with MEF2-VC and nTRIP6-VN together with blocking peptides 
corresponding to either ID1 or ID2 fused to mCherry and a nuclear localization sequence (NLS). As 
controls scrambled versions of the blocking peptides were used (ID1c, ID2c). Left panel, Venus 
complementation (Compl.) was imaged by confocal microscopy and representative images are 
shown (Scale bars: 10µm). Right panel, the number of cells showing Venus complementation is 
presented as percentage of transfected, mCherry positive cells (mean ±SD of three independent 
experiments). 
 
Transfection of the control peptides (ID1c, ID2c) had no influence on the interaction 
between nTRIP6 and MEF2C as 70% of the cells showed Venus complementation 
in the nucleus (Fig. 8), which is similar to the complementation observed between 
nTRIP6-VN and MEF2C-VC in the previous experiment (Fig. 7). In contrast, the 
number of cells showing complementation was reduced to 35% upon transfection 
with ID1 and to 20% upon transfection with ID2 (Fig. 8). This result confirms the 
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involvement of both N-terminal domains of nTRIP6 in its interaction with MEF2C. 
Taken together, nTRIP6, and not TRIP6 interacts with MEF2C in the nucleus of 
C2C12 myoblasts, the interaction is mediated via discrete protein-protein 
interaction domains in the N-terminus of nTRIP6 and blocking peptides can be 
used to specifically inhibit the interaction between nTRIP6 and MEF2C.  
 
If nTRIP6 is a transcriptional co-regulator for MEF2C, it should be recruited to the 
MEF2C binding region of MEF2C target genes. To address this question, I 
performed Chromatin Immunoprecipitation (ChIP) assays in C2C12 cells. As 
MEF2C target genes I chose Myomesin 2 (Myom2) (Potthoff et al., 2007), 
Myoglobin (Mb) (Bassel-Duby et al., 1992), Troponin 1 type 2 (Tnni2) (Nakayama 
et al., 1996) and Desmin (Des) (Kuisk et al., 1996; Li and Capetanaki, 1994), which 
all have well characterized MEF2C binding sites. The ChIP assay shows that 
indeed nTRIP6 as well as MEF2C are present at the MEF2C binding site of these 
genes (Fig. 9a). A re-ChIP was performed to confirm that both proteins co-occupy 
these promoter regions. After chromatin precipitation with the antibody against 
TRIP6, the chromatin was eluted and subjected to a second precipitation using an 
antibody against MEF2C. The experiment showed that nTRIP6 and MEF2C were 
present together at the MEF2C binding site of the MEF2C target genes (Fig. 9b). 
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Figure 9 nTRIP6 and MEF2C co-occupy MEF2C-dependent promoters 
a) Chromatin Immunoprecipitation (ChIP) was performed in C2C12 cells using the indicated 
antibodies (Ab). b) Chromatin immunoprecipitated with the anti-TRIP6 antibody was eluted and 
subjected to a re-ChIP using either the anti-MEF2C antibody or the corresponding isotype control 
antibody (IgG). (a-b) PCR was performed using primers flanking the MEF2C binding regions of the 
indicated genes. Gels from representative experiments are shown. 
 
Taken together, nTRIP6 interacts with MEF2C and is recruited together with 
MEF2C to the regulatory regions of MEF2C target genes. Therefore, given the 
reported role for nTRIP6 as a transcriptional co-activator for GR, AP-1 and NF-κB 
(Diefenbacher et al., 2008, 2010, 2014) nTRIP6 might act as transcriptional co-
activator for MEF2C. To address this question, I performed reporter gene assays 
in C2C12 cells using a MEF2C-dependent luciferase reporter construct. If nTRIP6 
acts as coactivator for MEF2C, the loss of nTRIP6 should decrease MEF2C 
transcriptional activity. C2C12 cells were transfected with an siRNA targeting Trip6 
mRNA in order to knockdown nTRIP6 or with a nonspecific siRNA as a negative 
control.  
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Figure 10 Silencing nTRIP6 increases MEF2C transcriptional activity 
a) C2C12 cells were transfected with either an siRNA targeting Trip6 mRNA or a control siRNA 
(Co). 24h post-transfection cells were transfected with a MEF2C-dependent luciferase reporter 
gene together with an expression vector for β-galactosidase for normalization and with an 
expression vector for MEF2C (+) or an empty vector (-). Normalized luciferase activity is plotted 
relative to the control siRNA, empty vector transfected cells (mean ± SD of three individuals 
experiments). b) After measurement of the luciferase activity, cell lysates were subjected to 
Western Blot analysis using the indicated antibodies, GR was used as loading control.  
 
In the reporter gene assay, the MEF2C-dependent reporter gene was efficiently 
activated via transfection with MEF2C. When nTRIP6 was silenced the activity of 
the reporter construct was significantly increased, while the basal activity was not 
affected (Fig. 10a). Western Blot analysis confirmed that the specific siRNA 
efficiently knocked down nTRIP6 expression without affecting MEF2C expression 
(Fig. 10b). This experiment shows that surprisingly, nTRIP6 does not increase 
MEF2C transcriptional as should be the case for a transcriptional co-activator, but 
rather represses it. However, since TRIP6 expression was also knocked down I 
cannot exclude an indirect effect due to the loss of this isoforms. To confirm that 
nTRIP6 regulates MEF2C activity, I studied the effect of overexpressing nTRIP6 in 
the same reporter gene assay. MEF2C activity was repressed by nTRIP6 in a 
dose-dependent manner, while the expression of MEF2C was not affected (Fig. 
11a).  
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Nevertheless, this still could be an indirect effect of overexpressed nTRIP6. Thus, 
I investigated whether the repression of MEF2C activity by nTRIP6 depends on the 
interaction between both proteins. nTRIP6 was not able to efficiently repress 
MEF2C activity when either the ID1 or ID2 interaction domains were deleted. 
(Fig.11a).  
 
 
Figure 11 MEF2C repression depends on its interaction with nTRIP6 
a) C2C12 cells were transfected with a MEF2C-dependent luciferase reporter construct, an 
expression vector for β-galactosidase for normalization, an expression vector for MEF2C (+) or 
empty vector (-), together with increasing amounts of either nTRIP6, nTRIP6 lacking the interaction 
domain 1 (∆ID1) or nTRIP6 lacking the interaction domain 2 (∆ID2). Normalized luciferase activity 
is plotted relative to the empty vector control. b) After measurement of the luciferase activity, cell 
lysates were subjected to Western Blot analysis using the indicated antibodies; GR was used as 
loading control. 
 
This result shows that a direct binding of nTRIP6 via the interaction domains is 
necessary to repress MEF2C transcriptional activity, further pointing towards a 
direct effect of nTRIP6. In order to further confirm that the repression of MEF2C 
activity is carried out by the direct binding of nTRIP6 to MEF2C, the genetically 
encoded ID1 and ID2 peptides were used to block the interaction in the reporter 
gene assay.  
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Figure 12 The blocking peptides increase MEF2C transcriptional activity 
a) C2C12 cells were co-transfected with a MEF2C dependent luciferase reporter gene, an 
expression vector for β-galactosidase for normalization, either an expression vector for MEF2C (+) 
or an empty vector (-), together with either an empty vector or the mCherry-NLS fusion of either the 
ID1 peptide, its scrambled version (ID1c), the ID2 peptide or its scrambled version (ID2c). 
Normalized luciferase activity is plotted relative to the empty vector control (mean ±SD of three 
independent experiments). b) After measurement of the luciferase activity, cell lysates were 
subjected to Western Blot analysis using the indicated antibodies; GR was used as loading control.  
 
While the control peptides did not have any influence on MEF2C activity, both 
blocking peptides increased the activity of MEF2C. However, ID2 was more 
efficient that ID1 (Fig. 12a). This result is in accordance with the previous 
observation that ID2 blocks the interaction between nTRIP6 and MEF2C more 
efficiently than ID1 (Fig. 8). For this reason, only ID2 was used for further 
experiments. Taken together, I demonstrated that nTRIP6 interacts with MEF2C 
and that both co-occupy the MEF2C response elements of MEF2C target genes. 
Moreover, nTRIP6 represses MEF2C transcriptional activity. Thus, nTRIP6 fulfills 
all criteria for beeing a transcriptional co-repressor for MEF2C. 
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3.2 nTRIP6 mediates the recruitment of HDAC5 to MEF2C target promoters 
 
What could be the mechanism of nTRIP6 co-repressor function for MEF2C? 
nTRIP6 does not harbour any catalytic activity or functional domains classically 
found in transcriptional co-repressors. We have previously reported that nTRIP6 
acts as transcriptional co-activator for other transcription factors by interacting via 
its LIM domains with and mediating the promoter recruitment of other co-regulators 
such as THRAP3, therebye acting as a bridging factor (Diefenbacher et al., 2014). 
A possible hypothesis is therefore that nTRIP6 recruits additional co-repressors to 
the promoter-bound MEF2C. Moreover, since nTRIP6 interacts with MEF2C via ist 
N-terminus, the LIM domains would still be available for recruiting further 
transcriptional co-regulators. Known co-repressors for MEF2C are class IIa 
Histone Deacetylases such as HDAC4 and HDAC5 (Lu et al., 2000a; McKinsey et 
al., 2000a, 2000b). Given the role for nTRIP6 as a bridging factor for other 
transcriptional co-regulators, I hypothesized that nTRIP6 mediates the recruitment 
of HDAC4 or HDAC5 to MEF2C-bound promoters. To investigate this hypothesis I 
first tested whether nTRIP6 interacts with HDAC4 and HDAC5 using the BiFC 
assay. Immunofluorescence staining showed that fusion of HDAC4 and HDAC5 to 
the N-terminal half of Venus did not hamper their expression or nuclear localization 
(Fig. 13a). The BiFC assay showed that nTRIP6 interacts with HDAC5 in the 
nucleus and that the interaction takes place via the LIM domains of nTRIP6. 
Interestingly nTRIP6 did not interact with HDAC4 (Fig. 13b). Given that the 
interaction between nTRIP6 and HDAC5 is mediated via the LIM domains and that 
nTRIP6 binds MEF2C via its N-terminal pre-LIM region, it is tempting to speculate 
that nTRIP6 is required for the interaction between MEF2C and HDAC5. 
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Figure 13 nTRIP6 interacts with HDAC5 
a) C2C12 cells were transfected with HA-tagged versions of either HDAC5 or HDAC4 fused to the 
N-terminal half of Venus (VN) and subjected to immunofluorescence analysis using an antibody 
against the HA tag. Nuclei were counterstained with DRAQ5. Representative images are shown 
(Scale bars: 10µm). b) C2C12 cells were transfected with expression vectors for either HDAC5-VN 
or HDAC4-VN and either nTRIP6, only the LIM domains of nTRIP6 or the pre-LIM region of nTRIP6 
fused to the C-terminus of Venus (VC). As a transfection control cells were transfected with an 
expression vector for mCherry fused to a nuclear export signal. Venus complementation (Compl.) 
was imaged by confocal microscopy and representative images are shown (Scale bars: 10µm). The 
number of cells showing Venus complementation is presented as the percentage of transfected, 
mCherry positive cells (mean ± SD of three independent experiments). 
Results	
	 49	
Thus, I tested whether the loss of nTRIP6 prevents the interaction between MEF2C 
and HDAC5. To do so nTRIP6 was silenced using the siRNA targeting Trip6 
mRNA, in C2C12 cells transfected with HDAC5 fused to the N-Terminal part of 
Venus and MEF2C fused to the C-terminal part of Venus (Fig. 14a). The siRNA 
efficiently knocked down nTRIP6 expression without affecting the expression of the 
BiFC constructs, as shown by Western Blot analysis (Fig. 14a). The loss of nTRIP6 
led to a significant decrease in the number of transfected cells showing an 
interaction between MEF2C and HDAC5, as compared to the cells that were 
transfected with the control siRNA (Fig. 14a).  
 
 
Figure 14 nTRIP6 mediates the interaction between MEF2C and HDAC5 
a) C2C12 cells were transfected with an siRNA targeting the mRNA of Trip6 or a control siRNA 
(Co). One day later the cells were transfected with Flag-tagged HDAC5 fused to VN and HA-tagged 
MEF2C fused to VC, together with mCherry fused to a nuclear export signal (NES) as a transfection 
control. b) C2C12 cells were co-transfected with HDAC5-Flag-VN and HA-MEF2C-VC together with 
the blocking peptide corresponding to ID2 or its scrambled version as a control (ID2c), both fused 
to mCherry and a nuclear localization sequence (NLS). a,b) Representative images are shown 
(Scale bars: 10µm). The number of cells showing Venus complementation is presented as a 
percentage of transfected, mCherry positive cells (mean ± SD of three independent experiments). 
Left panels: cell lysates from the experiments in (a-b) were subjected to Western blot analysis using 
the indicated antibodies. 
Results	
	 50	
Again, to exclude an indirect effect of the loss of TRIP6, the same BiFC experiment 
was performed in the presence of the ID2 peptide to block the interaction between 
endogenous nTRIP6 and MEF2C. Indeed, transfection of the blocking peptide 
significantly reduced the number of cells showing an interaction between HDAC5 
and MEF2C (Fig. 14b). These results show that nTRIP6, interacting with MEF2C 
via its N-Terminal pre-LIM region and with HDAC5 via its LIM domains, acts as a 
bridging factor for the interaction between MEF2C and HDAC5. This is compatible 
with the hypothesis that nTRIP6 acts by mediating the recruitment of HDAC5 to the 
promoter-bound MEF2C. To address this hypothesis, I first investigated by ChIP 
the occupancy of the MEF2C binding sites of MEF2C target genes by HDAC5 and 
nTRIP6. Indeed, both proteins were present at the promoter of the MEF2C target 
genes Myomesin 2 (Myom2), Myoglobin (Mb), Troponin 1 type 2 (Tnni2) and 
Desmin (Des) (Fig.15a). Furthermore, re-ChIP using the antibody against HDAC5 
after elution of chromatin precipitated with the anti-TRIP6 antibody confirmed that 
nTRIP6 and HDAC5 co-occupy the MEF2C binding site of these genes (Fig. 15b).  
 
 
 
Figure 15 nTRIP6 and HDAC5 co-occupy MEF2C dependent promoters 
a) Chromatin immunoprecipitation (ChIP) was performed in C2C12 cells using the indicated 
antibodies (Ab). b) Chromatin immunoprecipitated with the anti-TRIP6 antibody was eluted and 
subjected to a re-ChIP using either the anti-HDAC5 antibody or the corresponding isotype control 
antibody (IgG). (a-b) PCR was performed using primers flanking the MEF2C binding regions of the 
indicated genes. Gels from representative experiments are shown. 
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Finally, the putative bridging function of nTRIP6 was addressed. In the ChIP assay, 
the siRNA-mediated knockdown of nTRIP6 led to a reduction in the recruitment of 
HDAC5 to the MEF2C binding sites of MEF2C target genes (Fig. 16). Therefore, 
nTRIP6 acts as an adaptor co-regulator and recruits HDAC5 to the regulatory 
regions of MEF2C target genes. 
 
 
Figure 16 nTRIP6 mediates the recruitment of HDAC5 to MEF2C target promoters 
C2C12 cells were transfected with either an siRNA targeting the mRNA of Trip6 or a control siRNA 
(control). ChIP was performed using either an antibody against HDAC5 or an isotype control. 
Enrichments of the MEF2C binding regions of the indicated genes were determined by real Time 
PCR and plotted as percent of input. The results of 3 independent experiments are shown. N.D. : 
not detected. 
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To conclude this part, I have shown that nTRIP6 interacts with MEF2C via distinct 
domains in the pre-LIM region of nTRIP6. This interaction can be efficiently blocked 
by using a genetically encoded blocking peptide that competes with nTRIP6 for the 
binding to MEF2C. Moreover, nTRIP6 and MEF2C co-occupy the regulatory 
regions of MEF2C target genes leading to a repression of MEF2C activity. This 
repression is carried out by an nTRIP6-mediated recruitment of HDAC5 to the 
regulatory regions of MEF2C target genes. Thus, nTRIP6 acts as an adaptor-like 
transcriptional co-repressor for MEF2C. 
 
3.3 Role of nTRIP6 in adult myogenesis 
	
Given that nTRIP6 acts as a transcriptional co-repressor for MEF2C and that 
MEF2C drives the expression of differentiation genes during myogenesis, nTRIP6 
might play a role in the regulation of differentiation and fusion. As first step in 
investigating a possible function for nTRIP6 in myogenesis, I studied its expression 
during the differentiation of the C2C12 myoblast cell line.  
 
 
 
Figure 17 nTRIP6 expression is transiently increased prior to differentiation 
C2C12 were seeded at low density and kept in proliferation medium for 2 days (day -2 till 0). At day 
0 the medium was switched to low serum containing differentiation medium. Cells were harvested 
as indicated (day). Whole cell extracts were analysed by Western Blotting using an antibody against 
TRIP6 and nTRIP6. GR was used as a loading control. The relative expression of nTRIP6 and 
TRIP6 (ratio) was determined by quantifying the intensities of the respective bands on the blot (one 
representative blot shown) 
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While TRIP6 was expressed at constant levels during differentiation, nTRIP6 was 
barely detectable when the cells were at low density. nTRIP6 expression increased 
at the transition between late proliferation and early differentiation phase (from day-
1 to +1) and decreases afterwards (Fig. 17). Interestingly the transient increase in 
nTRIP6 expression occurs when MEF2C activity has to be repressed in myoblasts 
(Liu et al., 2014). This observation suggests that nTRIP6 might play a role in the 
regulation of myoblast differentiation.  
To investigate this hypothesis, I used the genetically encoded blocking peptide to 
block nTRIP6 function in myoblasts. As a readout, I analysed the expression of 
embryonic myosin heavy chain (MYH3), the first contractile protein that is 
expressed upon differentiation, and is classically used as a differentiation marker 
(Tomczak, 2003).  
 
 
Figure 18 Blocking nTRIP6 function leads to premature differentiation 
C2C12 cells were transfected with the ID2 blocking peptide or its scrambled version as a control 
(ID2c). After transfection, the cells were kept in proliferation medium for two days, then switched to 
differentiation medium (Day 0). Cells were harvested every day and whole cell lysate were analysed 
by Western Blotting using antibodies against MYH3 and GR as a loading control. Representative 
Western Blots are shown. The relative expression of MYH3, normalized to the expression of GR 
(ratio) was determined by quantifying the intensities of the respective bands on the blot (mean ± 
SD of three independent experiments).  
 
In cells transfected with the control peptide, the expression of MYH3 started at day 
1 after induction of differentiation (medium switch). However, when the blocking 
peptide was transfected myoblasts started expressing MYH3 one day earlier, 
before the cells were switched to differentiation medium (day =0). Moreover, at day 
Results	
	 54	
1 the expression of MYH3 was significantly increased as compared to the control 
(Fig. 18). Thus, in the presence of the nTRIP6 blocking peptide myoblasts 
differentiate too early. This result shows that nTRIP6 prevents the premature 
differentiation of myoblasts and thus plays a role in regulating the differentiation 
process.  
 
I then tested whether blocking nTRIP6 function in myoblasts affects the fusion 
process. I used again the genetically encoded blocking peptide and determined the 
fusion index, i.e. the percentage of nuclei within fused fibres. In cells transfected 
with the control peptide, fusion of myoblasts started slowly at day 1 and rapidly 
increased to reach a fusion index of about 40% at day 3. However, in cells 
transfected with the blocking peptide the fusion index was significantly lower at 
both day 2 and day 3 (Fig. 19). 
 
 
 
Figure 19 nTRIP6 function is required for proper fusion 
C2C12 cells were transfected with the ID2 blocking peptide or its scrambled version as a control 
(ID2c). After transfection cells were kept in proliferation medium for two days. Then the medium 
was switched to differentiation medium (Day 0). During the fusion process cells were fixed every 
day and stained with an antibody against MYH3 to visualize the fibres, an anti-mCherry antibody 
and DRAQ5 to visualize the nuclei. Quantification was done by counting all the fibres within 1mm2 
and the number of nuclei within the fibres. Results are presented as the fusion index, i.e. the 
percentage of nuclei within fused fibres, and plotted as mean ± SD of three independent 
experiments. 
 
These results show that although nTRIP6 blocks differentiation in myoblasts it is 
paradoxically required for proper fusion.  
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3.4 Role of nTRIP6 in muscle regeneration 
	
In order to address the in vivo relevance of my findings showing a role for nTRIP6 
in the regulation of myoblast differentiation in vitro, I investigated the muscle repair 
capacity of the conditional Trip6 knockout  mouse, in which the expression of TRIP6 
and nTRIP6 is lost only in satellite cells. Briefly, animals in which the Trip6 gene is 
flanked by LoxP sites (C57BL/6J-Trip6fl/fl) were crossed with mice expressing the 
tamoxifen-inducible Cre recombinase (Cre-ER-T2) only in satellite cells (Pax7CRE-
ER-T2/wt). The resulting C57BL/6J-Trip6fl/fl;Pax7CRE-ER-T2/wt animals were treated with 
tamoxifen to knockout the Trip6 gene in satellite cells. I will refer to these animals 
as Trip6scKO. The C57BL/6J-Trip6fl/fl;Pax7wt/wt animals were used as controls and 
are referred to as Trip6fl/fl.  
As a first step I assessed the recombination efficiency in this mouse model. To do 
so single myofibres were isolated from the extensor digitorum longus muscle of 
tamoxifen-treated Trip6scKO or Trip6fl/fl control animals and stained with an antibody 
against TRIP6/nTRIP6 and an antibody against PAX7 to identify satellite cells (Fig. 
20). 
 
 
 
Figure 20 Efficient Trip6 gene knockout in satellite cells 
Individual myofibres were isolated from extensor digitorum longus muscle of tamoxifen-treated 
C57BL/6J-Trip6fl/fl;Pax7CRE-ER-T2/wt (Trip6ScKO) mice or of C57BL/6J-Trip6fl/fl;Pax7wt/wt  (Trip6fl/fl) 
littermate control animals and stained with antibodies against TRIP6/nTRIP6, PAX7 to identify 
satellite cells and DRAQ5 to visualize the nuclei. Representative images are shown (scale bar: 
10µm). 
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Upon tamoxifen treatment, none of the PAX7 positive satellite cells showed any 
TRIP6 / nTRIP6 immunoreactivity (Fig. 20, quantification not shown), showing that 
the Trip6 gene was efficiently knocked out in 100% of the satellite cells. 
Muscle damage was induced by direct injection into the M. soleus of Notexin, a 
toxin from the venom of the Australian tiger snake Notechis scutatus. This toxin 
induces the complete degeneration of the muscle by destruction of the myofibres, 
without damaging the satellite cells (Dixon and Harris, 1996). Animals were 
sacrificed after 7, 10, 14 and 28 days of regeneration and the size of the 
regenerating myofibre was quantified as an index of regeneration (Fig. 21). 
 
In Trip6fl/fl (wt) animals, the size of regenerating myofibres had already reached 
about 50% of the fibre size in the non-damaged contralateral muscle after 7 days 
of regeneration. This size steadily increased until day 28 post-injury. Importantly, 
there was no significant difference in the size of the fibres in undamaged muscles 
of Trip6fl/fl and Trip6scKO mice (minimum Feret’s diameters of 26.6±3.2 µm and 
26.5±3.2 µm, respectively, mean ± SD, n=20). In the regenerating muscle of the 
Trip6scKO animals, after 7 days of regeneration the size of the regenerating fibres 
was larger than in the control animals, suggesting an accelerated regeneration 
process. This difference was no more observable at day 10 post-injury. However, 
at later time points, the size of the Trip6fl/fl fibres significantly increases from day 
10 to day 14, which was not the case for the Trip6scKO mice. Even after 28 days the 
fibres from the Trip6scKO mice did not reach the size of the Trip6fl/fl mice (Fig. 21).  
 
This impaired regeneration in the Trip6scKO mouse suggests defects in either the 
differentiation or the fusion of myoblasts. To directly address this question, I 
quantified the number of MYOD-expressing mono-nucleated myogenic cells, i.e. 
myoblasts and myocytes during regeneration.  
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Figure 21 Muscle regeneration is impaired in satellite cell specific Trip6 knockout mice 
Cross-sections of the undamaged and regenerating soleus muscle from either Trip6scKO or Trip6fl/fl 
littermate control animals were stained with an antibody against laminin to delineate the myofibres 
and with DRAQ5 to visualize the nuclei. Regenerating myofibres were identified by their centralized 
nuclei. a) Representative images are shown from Trip6fl/fl mice after 14d of regeneration (scale bar: 
100µm). b) Myofibre size was measured by automated segmentation of the individual myofibres 
and calculation of the minimum Feret’s diameter using ImageJ. The myofibre size is plotted as 
percentage of the undamaged contralateral leg (mean ± S.D. of groups of n=5). Statistical analysis 
was performed according to 2.2.6 of the methods section. 
 
Results	
	 58	
 
 
Figure 22 The number of unfused myoblasts/myocytes does not decrease during muscle 
regeneration in satellite cell specific Trip6 knockout mice 
Cross sections of soleus muscle from either Trip6scKO or Trip6fl/fl littermate control mice treated with 
Notexin were stained after 7, 10, 14 and 28 days of regeneration with an antibody against MYOD 
to visualize myoblasts and myocytes, an antibody against Laminin to delineate the myofibres with 
and DRAQ5 to visualize the nuclei. a) Representative images are shown from Trip6fl/fl mice (scale 
bar: 50µm). b) Quantification was performed by counting all MYOD positive mononucleated cells 
and normalizing this number to the number of fibres on the section (mean ± S.D. of groups of n=5). 
Statistical analysis was performed according to 2.2.6 of the methods section. 
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In the regenerating soleus muscle of the Trip6fl/fl control animals, the number of 
MYOD positive cells that were not fused started to significantly decrease after 10 
days of regeneration (Fig. 22). In the muscle of Trip6scKO mice, at the first day of 
regeneration I observed, 7 and 10 days post-injury, the number of non-fused 
MYOD positive cells was similar to that in the muscles of the control mice. 
However, from day 10 to day 14 this number of MYOD positive cells decreases 
significantly in the Trip6fl/fl animals but not in the Trip6scKO mice (Fig. 22). Therefore, 
the impaired regeneration in terms of fibre size upon knocking out the Trip6 gene 
in satellite cells appears to be due to an impaired differentiation and fusion of 
myoblasts. 
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4. Discussion 
 
In this work, I have uncovered a novel function for nTRIP6, the short isoform of the 
focal adhesion LIM domain protein TRIP6: it acts as a co-repressor for the 
myogenic transcription factor MEF2C in proliferating myoblasts. Furthermore, 
during adult myogenesis nTRIP6 expression is transiently increased directly before 
differentiation starts. Blocking its function results in a premature expression of late 
differentiation genes combined with a reduced myocyte fusion. Finally, in a model 
of muscle regeneration in the Trip6 knockout mouse, regenerated myofibres had a 
smaller size, and the regenerating muscle showed a higher number of unfused 
myogenic cells than in the control animals.  
 
4.1 nTRIP6 acts as transcriptional co-repressor for MEF2C 
	
In the first part of this thesis, I report a that nTRIP6 acts as a co-repressor for the 
transcription factor MEF2C in proliferating myoblasts. Transcriptional co-repressor 
can be defined as factors which do not directly bind DNA but are recruited to the 
regulatory regions of target genes through a direct or indirect interaction with DNA-
binding transcription factors, and which participate in the repression of 
transcription. I showed that nTRIP6 interacts with MEF2C via its N-terminal pre-
LIM region, is recruited together with MEF2C to the regulatory regions of MEF2C 
target genes, and represses MEF2C transcriptional activity. Thus nTRIP6 fulfils all 
criteria for being a transcriptional co-repressor for MEF2C. Although TRIP6 also 
harbours the domains in the nTRIP6 pre-LIM region that are responsible for the 
interaction with MEF2C, TRIP6 does not interact with MEF2C in the nucleus of 
proliferating myoblasts. This observation is in contrast to the reported findings in 
which other focal adhesion LIM domain proteins of the Zyxin family exert nuclear 
functions by shuttling between the focal adhesion sites and the nucleus upon, for 
example, changes related to regulation of focal adhesion (Cattaruzza et al., 2004; 
Mori et al., 2012; Yoshigi et al., 2005). In the nucleus, these focal adhesion LIM 
domain proteins can interact with a variety of nuclear proteins and transcription 
factors and influence their transcriptional activity (Wang and Gilmore, 2003). My 
results confirm that although TRIP6 belongs to the Zyxin family, its nuclear function 
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is not depending on signalling that induces TRIP6 translocation to the nucleus. Like 
its co-activator function for AP-1, NF-kB and GR (Diefenbacher et al., 2008, 2010, 
2014; Kassel et al., 2004), TRIP6 co-repressor function for MEF2C is exerted by 
the smaller isoform nTRIP6 which is exclusively present in the nucleus (Kassel et 
al., 2004). 
 
My results show that nTRIP6 acts as an adaptor co-repressor for MEF2C in 
proliferating myoblasts by mediating the promoter recruitment of HDAC5, but, 
surprisingly, not that of HDAC4, another related class IIa HDAC. The activity of 
both these known co-repressor of MEF2C in myoblasts (Lu et al., 2000a; McKinsey 
et al., 2000a) is mainly regulated via a common mechanism targeting their 
subcellular localization. HDAC4 and 5 contain a NES as well as an NLS. Upon 
phosphorylation of serine residues near the NLS sequence, the protein 14-3-3 
binds HDAC4 and 5 and masks the NLS. This leads to a nuclear export of both 
proteins (McKinsey et al., 2000b). My observation that nTRIP6 interacts with 
HDAC5 in the nucleus but not with HDAC4 suggests the existence of different 
mechanisms regulating HDAC4 and HDAC5 function in myoblasts. One may 
speculate that the interaction with nTRIP6 in the nucleus may be a mechanism to 
differentially regulate the nuclear export of both proteins: the interaction with 
nTRIP6 might be an active mechanism to retain HDAC5 in the nucleus. Such a 
difference in the regulation of HDAC4 and HDAC5 has already been observed in 
another context: in fast type myofibres, low frequency electrical stimulation induces 
the nuclear export of HDAC4 but not of HDAC5 (Liu et al., 2005). My observations 
further illustrate the complexity of MEF2C regulation by class IIa HDACs in 
myoblasts. 
By mediating the interaction between MEF2C and HDAC5 at the regulatory regions 
of MEF2C target genes, nTRIP6 acts as an adaptor co-repressor. A similar function 
of nTRIP6 has previously been reported in the regulation of AP-1, NF-kB and GR 
transcriptional activity where nTRIP6 acts as an adaptor co-activator by mediating 
the recruitment of THRAP3 (Diefenbacher et al., 2014). Thus nTRIP6 is able to act 
as either a co-activator or a co-repressor, depending on the transcription factor it 
interacts with. Other members of the Zyxin and Paxillin families of LIM domain 
proteins have been shown to be able to act as both co-activator and co-repressor. 
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For example HIC-5 is a co-activator for the androgen receptor (AR) and GR, and 
at the same time acts as co-repressor for SMAD and LEF/TCF (Ghogomu et al., 
2006; Wang et al., 2005).Similarly, AJUBA acts as a co-repressor for SNAIL (Hou 
et al., 2008) and as a co-activator for PPARg (Li et al., 2016). How can the same 
adaptor protein mediate the recruitment of either a co-activator or a co-repressor?  
When nTRIP6 co-activates AP-1 the interaction with the transcription factor occurs 
via its LIM domains (Kassel et al., 2004). However, when nTRIP6 co-represses 
MEF2C, the interaction with the transcription factor occurs via the pre-LIM region 
and not via the LIM domains. Could this difference in the mode of interaction with 
the regulated transcription factor be responsible for whether it acts as a co-activator 
or a co-repressor? Interestingly, when AJUBA acts as an adaptor co-repressor for 
SNAIL, it interacts with SNAIL via its LIM domains (Hou et al., 2008) and recruits 
the co-repressor PRMT5 via its pre-LIM region. However, when it co-activates 
PPARg, it interacts with this transcription factor via its pre-LIM region and recruits 
the co-activator p300/CBP via its LIM domains (Li et al., 2016). Thus, it seems 
tempting to speculate that the way by which focal adhesion LIM domain proteins 
interact with transcription factors may affect the ability of the LIM domains to 
interact with either a co-activator or a co-repressor. Another hypothesis would be 
that nTRIP6 recruits either co-activators or co-repressors depending on their 
availability or level in the nucleus. Indeed, MEF2C repression via HDAC5 takes 
place during myoblast proliferation, a time point where HDAC5 is present at high 
levels in the nucleus (Lu et al., 2000a; McKinsey et al., 2000b). Thus, nTRIP6 most 
likely interacts with HDAC5 because of its high levels in the nucleus. This 
hypothesis is strengthened by the role of nTRIP6 in the repressive crosstalk 
between AP-1 and GR (Jonat et al., 1990; Lucibello et al., 1990; Schüle and Evans, 
1991). In the absence of GR in the nucleus, nTRIP6 recruits the co-activator 
THRAP3 to AP-1-bound promoters. However, upon stimulation with 
glucocorticoids, GR translocates into the nucleus, interacts with nTRIP6, displaces 
THRAP3 and thus represses AP-1 activity (Diefenbacher et al., 2008, 2010; Kassel 
et al., 2004). Therefore, the availability of GR in the nucleus appears to be the 
prime determinant of the ability of nTRIP6 to act as an adaptor co-repressor for 
AP-1. These examples suggest that indeed nTRIP6 acts as co-activator or co-
repressor depending on the availability of other co-regulators in the nucleus. 
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During myogenesis, MEF2C drives the expression of genes that are involved in 
late differentiation, fusion and maturation (Hinits and Hughes, 2007; Potthoff et al., 
2007). However it is already expressed in proliferating myoblasts (Liu et al., 2014; 
Mokalled et al., 2012) and its activity must therefore be repressed. This repression 
is at least in part carried out by HDAC5 (Lu et al., 2000b; McKinsey et al., 2000b). 
My results showing that in proliferating myoblasts nTRIP6 co-represses MEF2C 
via HDAC5 suggest that nTRIP6 might participate in the inhibition of differentiation 
in proliferating myoblasts. 
 
4.2 Role of nTRIP6 in adult myogenesis 
 
As a first hint to a putative role for nTRIP6 during myogenesis, I have shown that 
its expression is regulated. nTRIP6 is expressed at very low levels at the beginning 
of myoblast proliferation. Its expression then strongly increases at the transition 
between late proliferation and early differentiation. nTRIP6 expression then 
decreases back to basal levels during late differentiation and fusion. Interestingly, 
nTRIP6 levels are at the highest when MEF2C is already expressed in myoblasts 
and its activity has to be repressed, and decrease when MEF2C activity is required 
for late differentiation. Given the function of nTRIP6 as a transcriptional co-
repressor for MEF2C, the dynamics of nTRIP6 expression during myogenesis is 
totally compatible with a role for nTRIP6 in the transient repression of MEF2C 
activity during late proliferation and early differentiation. Indeed, the loss of nTRIP6 
function led to the premature expression of late differentiation genes such as MYH3 
(this work), Myomesin 2, Troponin I2 and Myoglobin (Kemler et al., 2016) during 
the early differentiation phase. Since the expression of some of these structural 
genes such as Myomesin 2 and Troponin I2 is driven by MEF2C, the repression of 
their premature expression by nTRIP6 might be directly related to the co-repressor 
function of nTRIP6 for MEF2C. However, MYH3 is not a direct MEF2C target gene 
but rather a MYOD target gene (Tapscott, 2005). During myogenesis MEF2C alone 
is not sufficient to drive myogenic differentiation. MEF2C cooperates with MYOD 
and amplifies its transcriptional activity, and drives the expression of other MRFs, 
such as myogenin, that promote late differentiation (Buchberger et al., 1994; 
Molkentin et al., 1995; Ridgeway et al., 2000). It is tempting to speculate that 
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nTRIP6 regulates not only MEF2C but also MYOD activity by an indirect 
mechanism. For example, MEF2C is known to directly interact with MYOD at the 
promoter of MYOD target genes, acting as a co-regulator of MYOD (Badodi et al., 
2015; Molkentin et al., 1995; Sartorelli et al., 1997). It is therefore conceivable that 
MEF2C could mediate the recruitment of nTRIP6 to MYOD-bound promoters, 
leading to a transcriptional repression. Consequently, the loss of nTRIP6 function 
could also induce the premature activation of MYOD target genes such as MYH3. 
Interestingly, MYOD also drives the expression of p21 (Guo et al., 1995) and other 
cell cycle regulators that induce myoblasts to exit from the cell cycle (Andrés and 
Walsh, 1996; Guo et al., 1995; Walsh and Perlman, 1997). If nTRIP6 indeed 
controls their expression during the late proliferation phase, the loss of nTRIP6 
function might deregulate the coordinated transition between proliferation arrest 
and early differentiation. Such a mechanism might be responsible for the increased 
number of MYOD positive cells that I observed in vivo in the regenerating muscles 
when the trip6 gene was knocked out in satellite cells.  
 
In addition, nTRIP6 might not only play a role in preventing premature 
differentiation by acting as a co-repressor for MEF2C, and putatively indirectly for 
MYOD. Indeed, nTRIP6 has been reported to act as a co-activator for AP-1 and 
NF-kB (Diefenbacher et al., 2008, 2010, 2014; Kassel et al., 2004). Interestingly, 
both these transcription factors are known to promote proliferation of myoblasts 
and inhibit their differentiation by repressing the activity of MRFs (Lassar et al., 
1989; Li et al., 1992). Thus it is tempting to speculate that nTRIP6 might not only 
be able to block differentiation in myoblasts by co-repressing transcription factors 
that stimulate differentiation but also by co-activating transcription factors that 
repress differentiation. Taken together my results strongly suggest that the 
transient increase in nTRIP6 expression is essential to prevent the premature 
differentiation of proliferating myoblasts.  
 
Interestingly, although nTRIP6 has an anti-differentiation effect in proliferating 
myoblasts, at least in part by blocking MEF2C activity, my experiments also 
showed that, paradoxically, blocking nTRIP6 function in myoblast leads to an 
impaired myocyte fusion. The same effect was observed in vivo where 
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regenerating myofibres showed a smaller size when the trip6 gene was knocked 
out in satellite cells. However, in this model of regeneration both nTRIP6 and 
TRIP6, the long cytosolic isoform are knocked out and a combined effect due to 
the loss of both isoforms cannot be excluded. TRIP6, which is mainly located at 
focal adhesion sites, has been reported to be involved in the migration of cells (Bai 
et al., 2007; Lai et al., 2005, 2007). Satellite cells have been shown to be highly 
motile and migrate along the muscle fibres (Siegel et al., 2009). Thus, it is possible 
that when TRIP6 is lost, satellite cells fail to migrate to the location of the damage 
and consequently cannot contribute to the regeneration process. Furthermore, 
TRIP6 also plays a role in cytoskeleton dynamics (Lin and Lin, 2011; Sanz-
Rodriguez et al., 2004; Xu et al., 2004). During late myocyte differentiation and 
fusion, a massive re-arrangement of the cytoskeleton is needed to align the cells 
in a parallel fashion and to let them fuse. Immediately before fusion, a dense actin 
wall forms between the fusing cells that is supposed to give the correct membrane 
rigidity for the final fusion process (Duan and Gallagher, 2009). Then small gaps 
appear in the actin wall that form the fusion pore (Robertson et al., 1990). 
Therefore, the loss of TRIP6 in myocytes might interfere with these cytoskeletal 
rearrangement processes, leading to a defect in the fusion process during muscle 
regeneration in vivo. This has to be further investigated. Nevertheless, my in vitro 
data rather hint towards a role for nTRIP6 in fusion. Indeed, the blocking peptide I 
used specifically blocks the function of nTRIP6 in the nucleus, without influencing 
TRIP6 action in the cytosol. Yet the question remains: how can a nuclear protein 
such as nTRIP6 influence myocyte fusion? A direct effect of nTRIP6 at sites of 
myocyte fusion or a direct involvement in processes such as cytoskeletal 
rearrangement can be excluded because of the exclusive nuclear localization of 
nTRIP6. One possibility would be that nTRIP6 might be required for the expression 
of genes needed to drive fusion. However, the dynamics of nTRIP6 expression 
during myogenesis does not seem compatible with such an effect. Indeed, my 
results show that when myocyte fusion starts nTRIP6 expression has already 
decreased and is very low. Therefore, it seems rather unlikely that nTRIP6 is 
involved in the fusion process directly. This hints towards a rather indirect role in 
which nTRIP6 is required at earlier stages to then allow for a proper fusion at later 
stages. One logical hypothesis is that this effect of nTRIP6 on fusion is related to 
its differentiation inhibitory function. Indeed, the premature activation of MEF2C 
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due to the loss of nTRIP6 leads to the expression of proteins of the contractile 
apparatus already during late proliferation (this study and Kemler et. al. 2016). The 
premature presence of these huge protein complexes might interfere with the 
rearrangement of the cytoskeleton or with the formation of fusion pores. This might 
result in a failure of these myocytes to fuse either with each other or with existing 
fibres. This hypothesis would also explain my observation that in trip6 knockout 
mice many MYOD positive cells stay unfused during the regeneration process, 
even after 28 days of regeneration. These unfused cells are most likely the reason 
for the smaller size of the regenerated myofibres, since the growth of muscle fibres 
is depending on the fusion of myocytes with the existing fibres (Granata et al., 
1998). However, it is still unclear at which stage of the differentiation process the 
unfused MYOD positive cells are. Indeed, MYOD starts to be expressed in satellite 
cells upon activation, then its expression strongly increases during proliferation and 
differentiation and is reduced during late differentiation and fusion (Bentzinger et 
al., 2012). Therefore, it is possible that the MYOD expressing cells are stuck in the 
proliferation process, or that these cells have already undergone differentiation but 
fail to fuse with the regenerating myofibres. Additional experiments have to be 
performed in order to dissect these possibilities.  
 
4.3 Conclusion 
 
In this work I have uncovered a novel molecular function for nTRIP6, which was so 
far known as a transcriptional co-activator, as a transcriptional co-repressor for 
MEF2C in myoblasts. This work also illustrates the complexity of the regulation of 
MEF2C activity during myogenesis. Furthermore, my work revealed a novel role 
for nTRIP6 as a regulator of adult myogenesis. In conclusion, I propose a model 
(Fig. 23) whereby a transient increase in nTRIP6 expression during late 
proliferation and early differentiation of myoblasts prevents the premature induction 
of late differentiation genes and structural proteins, most likely through the co-
repressor function of nTRIP6 for MEF2C. This anti-differentiation function of 
nTRIP6 at these early time points appears to be required to allow a proper myocyte 
fusion at later time points. Thus, the temporal regulation of nTRIP6 expression 
modulates the dynamics of adult myogenesis by coordinating the transition 
between proliferation and differentiation. 
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Figure 23 Proposed model of nTRIP6 role in the regulation of adult myogenesis 
During the early stages of myoblast proliferation, the expression of nTRIP6 is very low. It then 
transiently increases during late proliferation, a time point at which MEF2C is already expressed 
but should be repressed. At this critical transition between proliferation and early differentiation, 
nTRIP6, expressed at high levels, acts as a transcriptional co-repressor for MEF2C by mediating 
the recruitment of HDAC5 to promoter-bound MEF2C. This transient repression of MEF2C activity 
prevents premature differentiation of myoblasts. nTRIP6 then decreases back to basal levels, 
allowing MEF2C to drive late differentiation and fusion. Importantly, the transient, early increase in 
nTRIP6 expression appears critical to enable a proper differentiation and fusion at later time points. 
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